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出的突變熱點和細胞毒性 T -淋巴細胞表位上。今次所發現的氨基酸改 
變，對於細胞引發免疫反應不重要，因病毒的潛伏期膜蛋白質基因與以 
前所發現的不同，呈現出不同序列多樣性。 
广 . 。 
ABSTRACT 
The cDNA of the Epstein-Barr vims (EBV) latent membrane protein (LMP 
2) genes from B95-8, CB 14022 and Raji cell lines were cloned into pGEM-T Easy 
, Vector and transfected into E. coli JM109. B95-8 cell line intermittently releases 
standard strain ofEBV whereas CB 14022 and Raji are lymphocytes transformed 
and immortalized by EBV isolated from nasopharyngeal carcinoma and Burkitt's 
lymphoma patient respectively. DNA sequences of LMP 2 were then analyzed by 
deoxyribonucleotide sequencing using the Sanger's dideoxy sequencing method. 
Results showed high degree of homology, ranging from 99.4% to 99.8%, between 
the three cell lines and the standard sequence of EBV derived from GeneBank. 
Amino acid sequence analysis detected 3 amino acid alterations in B95-8 (99.4% 
match), 2 in CB 14022 (99.4% match) and 3 in Raji (99.2% match). 
These amino acid substitutions were further analysed by computer nucleic 
acid analytical softwares for hydrophobicity, secondary structure and isoelectric 
point determination based on the DNA sequence obtained. Results revealed that 
these residue substitutions did not significantly affect the contexts ofhydrophobicity 
and conformation of the protein. Isoelectric point analysis even yielded results 
exactly coinciding with that of the standard. 
In addition, none of the nucleotide and amino acid substitutions identified in 
this study was located within the previously determined hot spots of mutations and 
cytotoxic T lymphocyte (CTL) epitopes of LMP 2 gene. As a result, the EBV LMP 
2 gene studied exhibited pattern of sequence polymorphism other than those 
reported previously, and the amino acid substitutions identified here might not be of 
importance for cell-mediated immunity. 
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The discovery of the Epstein-Barr Vims (EBV) can be traced to the end of the 
th 
19 century when Filatov and Pfeiffer first described an illness known as glandular 
fever^ later named infectious mononucleosis (IM)^, and is characterized by fever, 
malaise, tonsillar adenopathy, hepatosplenomegaly, lymphadenopathy and 
mononuclear leukocytosis.^ 
In 1932，Paul and Bunnell discovered high titers of spontaneously occurring 
heterophile antibodies (capable of agglutinating sheep red blood cells) in patients 
with infectious mononucleosis.^ During the 1940-50s, tremendous effort had been 
made in order to isolate and to culture the etiologic agent of IM but was proven 
unsuccessful.^ Until 1958, Dr. M. Anthony Epstein, after attending a seminar on 
African Burkitt's lymphoma (BL) given by a British surgeon Denis Burkitt, 
suspected that there might be a biological agent involved in the etiology ofBurkitt's 
6 7 8 
lymphoma.，，Finally in 1964, Epstein and associates discovered a new particle 
resembling the icosahedral herpesvirus in the tumor biopsies from patients with 
Burkitt's lymphoma. The newly discovered vims was named after Epstein and his 
graduate student Yvonne Barr.^ 
In 1968, a female technician in Henles' laboratory seroconverted to EBV during 
the course of acute IM and that her peripheral blood leukocytes were taken and 
could be cultured to produce an immortalized EBV-carrying lymphoblastoid cell line 
1 
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(LCL)，thus providing the evidence that EBV is the causative agent of infectious 
mononucleosis.io This was further confirmed by large-scale epidemiological studies 
revealing the seroconversion to high titers ofEBV-specific antibodies in heterophile 
antibody-positive infectious mononucleosis individuals.^ '^^ '^^ '^^ ^ 
� 
Despite the fact that Epstein-Barr vims causes infectious mononucleosis, a 
more astonishing issue concerning EBV is its association with human cancers. As 
mentioned before, since the first detection of EBV in Burkitt's lymphoma biopsies, 
it was suspected that the vims might play a role in transforming normal cells into 
malignant phenotype. This hypothesis was later proved to be true by two 
independent groups of researchers reporting that EBV was capable of transforming 
human B lymphocytes into immortalized lymphoblastoid cell line (LCL) in vitroP' 
16 At present, EBV is known to be one of the viruses associated with human cancer 
including Burkitt's lymphoma, nasopharyngeal carcinoma, Hodgkin's disease and T-
cell lymphoma. 
1.2 Classification 
Epstein-Barr vims, also named human herpes vims 4 (HHV4), is classified into 
the family Herpesviridae, y-Herpesvirinae, genus Lymphocrytovirus. At present, the 
herpes family consists of eight members^ which are all large double-stranded DNA 
viruses. Being the prototype of lymphocryptovirus, EBV infects and becomes latent 
in lymphoid cells. EBV itself can be fUrther subdivided into EBV-1 and EBV-2 
according to their genomic sequences. EBV-1 is equivalent to the standard strain 
B95-8. Both strains basically share a high degree of sequence homology and have 
2 
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similar restriction endonuclease sites.^^ Their genomes differ only in the sequences 
of a set of genes expressed during latent infection. The Epstein-Barr vims nuclear 
antigens (EBNA) include EBNA 2, EBNA LP^^ EBNA 3A, 3B, 3C^^ and two small 
nonpolyadenylated RNAs, EBER 1 and EBER 2?^ Other latent genes such as latent 
� 
membrane protein (LMP) 1 & 2 only differ slightly between strains and the 
differences are not ofbiologic significance.^^'^^'^^ Both EBV-1 and EBV-2 are widely 
distributed and co-infection ofboth strains had been reported. 
1.3 Virus and genome structure 
The nucleic acids of EBV wrap around a toroid-shaped protein core surrounded 
by an icosahedral capsid consisting of 162 capsomeres. The diameter of the 
nucleocapsid is about lOOnm. Between the nucleocapsid and the outer envelope is a 
protein tegument. Surrounding the nucleocapsid and the protein tegument is the 
outer envelope which is rich in lipid. The outer envelope is derived from the 
membrane of the host cell where the virus replicates itself and buds off.^ '^^ '^^ ^ The 
outer envelope consists of many external glycoprotein spikes. Of these 
glycoproteins, gp350/220 is most abundant and represents the major immunogenic 
component which differentiates EBV from other members in the herpes family.^^ By 
electron microscopy, the diameter of a whole virion is about 180-220nm. 
Among all the herpes viruses, EBV genome was the first to be completely 
cloned into E. coli and sequenced.^ '^^ '^^ '^^ ^ The EBV genome consists ofalinear, 172 
kbp, double-stranded DNA composed of a 60 molar percentage of /^  p 
guanine/cytosine. The whole genome encodes for about 80 proteins.^^ A special 
3 
Introduction 
feature about the EBV genome is its overall pattern and gene arrangement. Both 
terminals of the linear genome are flanked with tandemly reiterated terminal direct 
repeats (TR) of 500 bp27'28,29 which join together and form a circular episome after 
the genome entering into the cell. Aside from the TRs, the genome contains a total 
X 
o f 4 internal direct repeats (IR) of which IR1 consists of a 3-kbp repeated sequence 
that divides the whole genome into unique long (UL) and unique short (US) 
regions.30’3i，32,33’34 These repeats are of great importance since they form the basis by 
which EBV strains are distinguished.^^ In addition to this, the tandem repeat 
reiteration frequency also provides a clue on whether the EBV latently infected cells 
for example, Burkitt's lymphoma cells and nasopharyngeal carcinoma cells^^, arise 
from a single progenitor. This is because each EBV latently-infected cell will have a 
certain frequency of such tandem repeats and this frequency tends to be conserved in 
• 37 
a lineage of cells The linear and episomal form of the EBV genome are shown in 
fig. 1 and fig. 2 respectively. 
The open reading frames (ORFs), genes or sites for transcription of EBV are 
usually referred to as BamRl fragments since the EBV genome was sequenced from 
a cloned library of EBV DNA BamRl fragments.^^' ^^  For example, the integral 
membrane protein LMP 1 is designated as BNLF-1 which means BamBJ, N 




TR: Terminal repeat 
U: Unique region 
IR: Internal repeat 
Fig. 1 Organization of the Linear genome of EBV 
showing the repeated regions. 
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1.4.1 Prevalence of infection 
EBV is ubiquitous in all parts of the world. Seroepidemiologic studies have 
� revealed that in many populations worldwide, approximately 90% to 95% of adults 
are serologically positive to EBV. Primary EBV infection manifests clinically as 
infectious mononucleosis (IM). However, not all cases of primary infection end up 
with infectious mononucleosis. Primary EBV infections are commonly acquired 
during childhood and the outcomes are primarily s u b c l i n i c a l，T h e r e a f t e r , the 
infected children are immune to EBV associated with IM.^ ^ However if primary 
infection is delayed until the age of ten and beyond, approximately 50% ofthem will 
develop IM if infected by EBV. Infectious mononucleosis is apparently a disease of 
persons 15-25 years of age and the highest incidence ofIM in the United States had 
been observed in this age group. Unlike influenza, there is no known seasonal 
changes in the incidence of IM and no wide-spread epidemics of IM have been 
r e p o r t e d . 4 9 Moreover, the incidence ofIM does not show any bias towards g e n d e r . 
The geographic distribution of EBV infection and clinically apparent IM co-
relates with socioeconomic conditions of the region. Close contact between persons 
is one of the main route of transmitting EBV. In industrialized countries or areas 
enjoying good hygiene, over 50% of EBV infections occur at the age of late 
adolescence and early adulthood.^^ Some of the cases are asymptomatic but half of 
them suffer from the clinically disease apparent of IM. In contrast, in developing 
countries, most of the infections occur during early childhood. Before the age of six, 
over 90% of children are infected with EBV but rarely become clinically apparent.^^ 
6 
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1.4.2 Modes of transmission 
Since low titers ofEBV are detected in 12%-25% ofseropositive individuals^^ 
and the majority of EBV infections occur at the age of adolescence and early 
adulthood, transmission of EBV is suspected to be through oral contact and 
� . 
respiratory secretions especially during the age of young adults where kissing with 
saliva exchange becomes more prevalent.^^ Supporting evidence had shown that the 
parotid glands might be sites ofEBV replication as EBV sequences and antigens had 
been identified in the parotid duct.^ ^ Latent infection of EBV in the lymphoid cells, 
mostly likely B cells, can act as a source which intermittently release infective 
viruses, thus suggesting that transmission can occur through blood transfusion and 
organ transplantation. Possible transmission through sexual intercourse is supported 
by the evidence that infective EBV were detected in the uterine cervix.^^ 
1.5 Pathogenesis ofEBV 
1.5.1 Adsorption, penetration and dissemination 
EBV establishes primary infection in its human hosts in the oropharyngeal 
epithelial cells. Attachment ofEBV to these cells is through the major viral envelope 
glycoproteins gp350/gp220 to the cellular CR2 complement receptor, (the receptor 
for the C3d component of complement) or CD21 which are located on the cell 
52 53 
surface.， After entering the cell, the vims undergoes the productive cycle by 
expressing a set of lytic cycle genes (see below). As a consequence, progeny EBVs 
were produced followed by the lysis of host cells. Part of the newly produced 
infectious EBVs are released into the saliva as a way of spread. Others virions may 
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infect the patrolling B lymphocytes infiltrating the lymphatic tissue of the 
oropharygneal mucosa by which dissemination of EBV throughout the host can be 
achieved. EBV utilizes the same mechanism to gain entry into the B lymphocytes as 
in the case of oropharygneal epithelial cells. The vims receptors CD21, in addition 
� 
to oropharyngeal epithelial cells, are also found on the surfaces o f B lymphocytes. In 
fact, EBV binds more efficiently to B cells than epithelial cells. After the 
nucleocapsid enters the nucleus of the B cell, the linear viral genome circularizes 
itself and becomes fused through the termini.^^' ^^  The EBV genome usually exists as 
an episome which is replicated by cellular DNApolymerase into multiple copies and 
located extrachromosomally.^^ Within B cells where EBV normally does not 
replicate, the virus establishes latent infection and expresses a set of latent genes 
which confer immortality of the B cells. 
1.5.2 Lytic infection cycle 
In vivo, EBV undergoes lytic replication almost only in epithelial cells of the 
nasopharynx, salivary glands and the parotid gland. EBV-immortalized B 
lymphocytes seldom become lytic and produce very little or no vims at all. 
However, cultures of these B cells can be induced to the lytic cycle in vitro by 
treatment with phorbol esters, calcium ionophores or cell surface immunoglobulin 
cross-linking.57，58，59 Cell lines harboring EBV are often activated byphorbol esters to 
induce production of infectious viruses for example, B95-8 and Raji cell lines. The 
mechanism of activation by phorbol esters is through the expression of the EBV 
immediate-early gene BZLF which acts as a transactivator of EBV lytic cycle.^^ 
Translation of the 1 kb BZLF mRNA gives rise to a protein called ZEBRA which 
brings about a cascade of events leading to the production of EBV early gene (EA) 
8 
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p r o d u c t s . 6 0 These are the non-structural proteins such as thymidine kinase and DNA 
polymerase which are required for viral replication. In addition to these early 
proteins, structural viral proteins (late gene products) such as viral capsid antigen 
(VCA), gp350/220 and gp85 are produced at the late stage of the lytic cycle. The 
� 
most abundant major vims coat glycoprotein, gp350/220, binds to the complement 
receptor CR2, mediating entry of the vims. The function of gp85 is to mediate 
fusion of the viral particle with the vesicle membrane thus releasing the 
nucleocapsid into the cytoplasm. The expression of early antigens such as the 
ZEBRAprotein and late proteins such as vims capsid protein VCA signifies that the 
vims is undergoing lytic cycle and that the outcome is the production of a large 
quantity ofprogeny virions followed by lysis of the host cell.^^ 
1.5.3 Latent infection cycle 
The latent infection cycle of EBV is considered to be most intriguing and 
complicated. Latently infected B cells act as a reservoir for EBV persistence in the 
host although they intermittently produce infectious viral particles.^^ The impact of 
the life-long persistence ofEBV on the host is still unknown but is believed to play a 
role in the oncogenesis of EBV-related cancers such as African Burkitt's lymphoma 
(BL), nasopharyngeal carcinoma (NPC) and Hodgkin's disease (HD). 
Nevertheless, EBV is known to exhibit itself in a variety of latent patterns of 
infection and the nuclear antigens EBNA 1 is constitutively expressed in all patterns 
of latency. The genetically most complex type of latency is the in vitro infection of 
primary resting B lymphocytes by EBV. Approximately 10% of the cell in culture 
are transformed to continuous cell line after exposure to EBV.^ ^ The resulting 
immortalized cell line is called lymphoblastoid cell line (LCL) and each ofthese cell 
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may contain between 1 to 10 copies of EBV episomes.^^' ^^  They proliferate 
indefinitely, expressing B cell activation marker CD23 and producing 
immunoglobulin.48 In addition, these EBV latently infected B cells express a 
restricted set of latent gene products including EBNA 1, 2，3A, 3B, 3C, and the 
n 
leader protein EBNA LP, three latent membrane proteins LMP 1, LMP 2A and LMP 
2B and two untranslated small nonpolyadenlylated RNAs EBER 1 and 2. Although 
only 10% ofthe genes are transcribed during latent cycle, the nine latent proteins are 
required to maintain EBV in a state of latency within the B cells and to mediate B 
cell proliferation. 
The second pattem of latency is revealed in Burkitt's lymphoma (BL) tumor 
biopsy and in vitro early passage BL cell lines7^ Unlike the gene expression pattem 
in LCLs, the only latent viral proteins expressed are the EBNA 1 as well as the 
EBERs.65，66 
The third as well as the last latency pattem is observed in nasopharyngeal 
carcinoma (NPC) and Hodgkin's disease (HD). In addition to EBNA 1 and EBERs 
which are expressed in BL, the two latent membrane proteins LMP 1 and LMP 2 are 
nf^ also expressed. 
1.5.4 Functions of the EBV-speciflc proteins associated with latent infection 
1.5.4.1 EBNA1 
The EBNA 1 (Epstein-Barr Nuclear Antigen 1) gene encodes for a highly 
charged protein with a molecular weight of 76 kd, consisting of 641 amino acids.^^ It 
contains an irregular glycine-alanine repeat which differs in various EBV strains.^^ 
During mitosis of EBV latently infected cells, EBNA 1 is the only EBNA that 
10 
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associates with cellular chromosomes.^^ EBNA 1 is essential for the maintenance 
and replication of the episomal form of EBV DNA in latently infected cells since it 
interacts with specific sequences within the oriP, the origin of plasmid DNA 
replication.70 In addition, EBNA 1 also acts as a transactivator of EBNA 2 which in 
tum activates the other two latent membrane proteins, LMP 1 and 2, and a number 
o f B cell gene products such as CD21, CD23 and c-fgr. EBNA 1 is expressed in 
Burkitt's Lymphoma cells where other EBNAs are absent. It is also constitutively 
expressed in EBV-associated Hodgkin's lymphoma and NPC cells. 
1.5.4.2 EBNA2 
EBNA 2 protein is an acidic molecule consisting of 491 amino acids (90 kd) in 
type 1 EBV while in type 2 EBV, it is only 443 amino acids long with a molecular 
weight of78 kd7^ It is expressed immediately following infection o f B lymphocytes 
by EBV. EBNA 2 is known to be a transcriptional transactivator which up-regulates 
the transcription of cellular genes encoded for the B cell activation marker CD23, 
the B cell differentiation marker CD21 and the cellular oncogene c-frg and the two 
EBV latent membrane proteins LMP 1 and LMP 2. In addition, EBNA 2 is essential 
in the transforming of normal human B lymphocytes. This was revealed by the 
inserting of cloned type 1 EBV EBNA 2 gene into a transformation-defective EBV 
derived from P3HR-1 cell line. The transformation efficiency of the resulting EBV 
strain was drastically increased7^ As mentioned before, type 1 and 2 EBV strains 
differ in their sequences in the EBNA 2 gene. Generally speaking, type 1 EBV (B95-
8) strain transforms more efficiently than type 2 EBV7' 
1.5.4.3 EBNA 3A, 3B and 3C 
The EBNA 3 family is composed of three members EBNA 3A, 3B and 3C 
which are encoded by separate genes. They are high molecular weight hydrophilic 
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proteins ranging from 145 to 165 kd but are the least abundant EBNA mRNAs with 
only a few molecules in each latently infected cell/^ Similar to EBNA 2, different 
strains of EBV express different EBNA 3 but unlike EBNA 2，the phenotypic 
differences between different strains do not affect the ability of the vims to initiate 
> 
growth transformation, episome maintenance or to replicate in response to induction 
ofpermissive infection7^ As a result, the type specificity ofEBNA 3 genes does not 
make a difference in the growth transformation of B cells in vitro. EBNA 3B is not 
essential for B lymphocyte transformation and containing mutated EBNA 3A or 
EBNA 3C gene are shown to be transformation incompetent7^ Although EBNA 3B 
is not essential for immortalization of B cells, recent data suggest that it may be able 
to stimulate the expression of the oncogene bcl-2 thereby contributing to the overall 
anti-apoptotic effect.^^ In summary, the functions of EBNA 3, the protein modulates 
LMP 1 and LMP 2 transcription by preventing EBNA 2 transactivation ofthe LMP 1 
and LMP 2 promoters7^' ” 
1.5.4.4 EBNALP 
EBNA LP (Leader Protein) is encoded by the leader of each of the EBNA 
mRNAs. Its function in latently infected B cells is largely unknown. Nevertheless, 
EBNA LP is required for efficient transformation of primary B cells since EBNA LP 
nonsense mutant recombinants were also deficient in cell growth transformation/^ It 
had been speculated that EBNA LP can directly or indirectly upregulate the 
expression of an autocrine factor critical for lymphoblastoid cell line (LCL) 
outgrowth80 and may associate with EBNA 2 together to induce transition from Go to 




LMP 1 (Latent Membrane Protein 1)，also called Terminal Protein 1 (TP 1), is 
an integral membrane protein which is consistently expressed in BLCLs and NPC 
cells. According to the predicted primary amino acid sequence, LMP 1 is composed 
� 
of three domains: a short hydrophilic amino-terminus consisting of 20 amino acids; 
six hydrophobic alpha helical transmembrane segments separated by five reverse 
tums, approximately eight to ten amino acids long and a highly charged carboxyl 
terminus consists of200 amino acids and enriched in acidic residues. About half of 
the LMP 1 molecules are located in the plasma membrane where it forms discrete 
patches and are further assembled into a single cap-like stmcture.^^ The amino-
terminal cytoplasmic domain is not essential while the transmembrane domain and 
the carboxyl terminus are required for primary B lymphocyte growth 
t r a n s f o r m a t i o n . 9 5 After the translation of LMP 1, it is phosphorylated on serine and 
threonine residues and is firmly bound to vimentine which is a structural component 
Q ) 
of filaments and microtubules. The vimentine cap, colocalizing with LMP 1, in 
tum is a key cytoskeletal element that directly or indirectly links LMP 1 to the 
83 
cytoskeleton. Unlike growth factors receptors, which form patches and caps in 
response to binding of growth factors, LMP 1 constitutively forms patches in LCL in 
the absence of ligand binding.^^' ^^  As a result, it is believed that LMP 1 mimics a 
constitutively active receptor molecule and affects the normal signal transduction. 
Besides, LMP 1 has been shown to transform continuous rodent fibroblast lines such 
as NIH-3T3 and Rat-L^^ By transfecting LMP 1 gene into these cell lines, LMP 1 is 
capable of inducing transformed cell phenotypes such as alteration of cell 
morphology, reducing serum requirement, lost of contact inhibition and anchorage 
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dependence and ability to grow in monolayers and soft agar.^^ Rat-1 cells are 
normally non-tumorigenic but when LMP 1 is expressed, it becomes tumorigenic.^^ 
Moreover, LMP 1 induces cell clumping, increased villous projections, vimentine 
expression, expression of cellular receptors CD23, CD39, CD40, CD44 , MHC class 
’ n proteins and cell adhesion molecules LFA-1, ICAM-1 and LFA_3^ These 
adhesion molecules facilitate cell growth in that they help to concentrate the 
autocrine growth factors secreted by proliferating B lymphocytes. On the other 
hand, these adhesion molecules promotes the conjugation between the B and T 
lymphocytes.88 This is important as this increased conjugation will enhance the 
affmity of effector-target conjugate formation thus facilitating cytotoxic T 
lymphocyte targeting.^^ Therefore, in vivo elimination of latently infected B cells 
becomes more efficient. Coupling the countervailing effects by the expression ofthe 
adhesion molecules LFA-1, ICAM-1 and LFA-3, the number of latently infected B 
cells remains more or less unchanged and thus leading to host survival and the 
continuance of viral lytic and latent infections in the host. Recently, LMP 1 is shown 
to be able to up-regulate expression of the cellular oncogene bcl-2 and A20 which in 
tum prevents the cells from undergoing programmed cell death (apoptosis).^^ 
1.5.4.6 Characteristics ofEBV Latent Membrane Protein 2 gene (LMP 2) 
The EBV LMP 2 gene is simultaneously transcribed under the control of two 
promoters separated by 3 kb giving rise to LMP 2A and LMP 2B, also named as 
terminal protein (TP) 1 & 2.n6'ii7,ii8 The LMP 2 gene contains exons located at both 
ends ofthe linear EBV genome and can be transcribed only across the fused termini 
ofthe episomal form ofEBV DNA or in some rare integrated events.u?’ u8，120 丁界。 
distinct forms of mRNA encode the 54 and 40kDa LMP 2A and LMP 2B membrane 
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proteins r e s p e c t i v d y . u ? The two distinct LMP 2 mRNAs of 1.7 kb and 2.0 kb have 
unique first exons located in the Ltregion and share exons 2 to 9 in the Us region as 
shown in fig.3. The LMP 2A mRNA encodes for a protein of478 amino acids and 
its primary amino acid sequence includes 119 amino acids at the amino-terminus, 12 
X 
hydrophobic domains of at least 16 amino acids each of which transverse the plasma 
membrane, and a 27 amino acid carboxyl-terminal domain]i8 The unique first exon 
of LMP 2A (exon lA) encodes the hydrophilic cytoplasmic amino terminus while 
the first exon of LMP 2B is non-encoding. As a result, both LMP 2A and LMP 2B 
share the 12 hydrophobic transmembrane domains and carboxyl-terminal domain 
but LMP 2B lacks the first exon of LMP 2A encoding the hydrophilic cytoplasmic 
amino terminus (fig. 4). Translation of LMP 2B initiates at a methionine codon at 
the beginning of the common second exon and codes for an extremely hydrophobic 
protein which is much less antigenic than LMP 2A/^^' u8 LMP 2A and LMP 2B co-
localize with LMP 1 to form patches in the plasma membrane of latently infected B 
cells.i20 
1.5.4.7 Functions ofLMP 2A 
LMP 2A is a substrate for the B lymphocyte src family of tyrosine kinases, 
specifically Lyn and fyn, and associates with a 70-kd tyrosine phosphorylated 
cellular protein/^ '^^ ^ '^^ ^^ Deletion analysis has shown that the first 167 amino acids 
of LMP 2A and the first two transmembrane domains are sufficient to interact with 
and act as a substrate for tyrosine kinase.^^^' ^^ ^ In fact, the amino-terminal domain of 
LMP 2A contains eight tyrosine residues that are phosphorylated in EBV-infected 
LCLs and in cells transfected with LMP 2A.^ ^ '^ ^^ ^ LMP 2A has the ability to 
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immunoglobulin a and p chain of the cytoplasmic domains of the B cell receptor 
(BCR), also named immunoreceptor tyrosine-based activation motif (ITAM), cluster 
with adjacent B cell receptor ITAMs following extracellular crosslinking ofantigen. 
This clustering leads to the phosphorylation of the ITAM tyrosines by the src family 
X 
of tyrosine kinases. The phosphorylated ITAM in tum becomes a binding site for a 
second type of tyrosine kinase, namely syk, which binds and becomes activated to 
phosphorylate other cytoplasmic proteins. In tum, such process activate various 
signaling pathways that eventually leading to the rapid activation of second 
messenger proteins. The final outcome included phosphoinositide hydrolysis, 
elevation of intracellular calcium concentration and gene transcription resulting in B 
cell proliferation, differentiation and antibody secretion.i24’i25，i26 
It has been shown that the constitutive expression of LMP 2A in an EBV-
negative Burkitt's lymphoma cell line resulted in a diminished calcium mobilization 
compared with control cells containing vector alone when the BCR, CD19 or MHC 
class II receptors are crosslinked/^^ In LCLs transformed by wild-type EBV, the 
amino-terminal cytoplasmic domain of LMP 2A is constitutively phosphorylated at 
the tyrosine residue and is associated with the src family and syk tyrosine kinases.^^^ 
Therefore, upon crosslinking of BCRs, the mediators leading to the activation and 
proliferation of B cell fail to be activated and the tyrosine phosphorylation in LMP 
2A remains stable after BCR crosslinking.^^^ 
In LCLs infected with wild-type EBV, there is no change in the intracellular 
calcium and lytic infection is not activated after BCR crosslinking. In contrast, 
crosslinking ofBCR on cells transformed by LMP 2-null EBV recombinants triggers 
the same cascade of reactions mentioned above, resulting in the increase in 
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intracellular free calcium and the latent EBV switch to lytic replication.^，i28 
Therefore, LMP 2 expressed on the surface of EBV latently infected B cells 
mimics the ITAM of B cell receptor in that the LMP 2A amino-terminal domains, 
when aggregated and complexed with the src family and syk tyrosine kinases, may 
X 
resemble crosslinked cell-surface receptors in the plasma membrane of EBV-
infected cells. The major role ofLMP 2A in latent EBV infection may be to prevent 
the activation of lytic EBV replication by blocking normal B cell signal 
transduction. 
LMP 2 has long been speculated to play a role in the transformation o f B cells 
as it is consistently expressed during latent infection and in NPC cells. However, 
recent studies on the in vitro role in transformation played by LMP 2A contradict 
with early findings.^^^ In this study, an EBV LMP 2A mutant which is defective in 
expressing LMP 2A, is capable of initiating and maintaining primary B lymphocyte 
growth in vitro. In addition, EBNA 1, EBNA 2 and LMP 1 expression is unaffected 
by the LMP 2A mutation. Most importantly, the BLCLs derived from these LMP 2A 
mutants are indistinguishable from wild-type EBV-transformed BLCLs in terms of 
their patterns of growth, permissiveness and vims replication.^^^ 
1.5.4.8 Functions ofLMP 2B 
LMP 2B lacks the 119 amino acids amino-terminal domain of LMP 2A and 
therefore does not possess the ability to block B cell signal transduction and 
reactivation of latent EBV infection as LMP 2A does. There is as yet no known 
function of LMP 2B reported but Longnecker and Miller^^ speculated that LMP 2B 
may be a negative regulator of LMP 2A activity by increasing the spacing between 
the amino-terminal receptor-like tail domains of individual LMP 2A molecules in 
the LMP 2 aggregates in the plasma membrane, resulting in the release of the src 
18 
Introduction 
family and syk tyrosine kinases from LMP 2A and thus restoring normal signal 
transduction through the BCR. Offsetting the antagonistic effects between LMP 2A 
and 2B would be the net overall outcome. And since LMP 2A and 2B are controlled 
under two separate promoters, therefore this variable outcome may depend on the 
’ environment within the host cell. 
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1.6 Clinical significance of EBV 
Epstein-Barr virus is ubiquitous and causes a variety of diseases in human with 
different degree of severity. Mild disease caused by EBV includes infectious 
mononucleosis (IM) whereas African Burkitt's lymphoma (BL), nasopharyngeal 
� 
carcinoma CNPC) and Hodgkin's disease (HD) are equally life-threatening. Other 
fatal diseases include oral hairy leukoplakia, X-linked lymphoproliferative 
syndrome and T-cell lymphoma. 
1.6.1 Infectious Mononucleosis (IM) 
The manifestation of IM is greatly dependent on the age of the infected 
persons. In infants and young children, EBV infections are asymtomatic or very 
mild48 but sometimes they may exhibit rashes, neutropenia or pneumonia.^^ 
However, when infection is delayed until adolescence, as happened in developed 
countries, the result is often infectious mononucleosis. IM is a primary infection 
seen predominantly in the 15-25 year age group. The incubation period is 30 to 50 
days and the onset is abrupt with a sore throat, cervical lymphadenopathy and fever, 
accompanied by malaise, headache, sweating and gastrointestinal discomfort.^ 
Appearance of atypical lymphocytes and production of heterophile antibody are 
phenomena observed during the clinical course.^ The illness can last several weeks 
but is self-limiting. Most IM patients recover with rare cases of complications. 
1.6.2 Burkitt's lymphoma (BL) 
EBV is associated with the development ofBurkitt's lymphoma, a tumor ofthe 
jaw commonly seen in African children and young adults. Burkitt's lymphoma is 
seen in the regions of equatorial Africa and New Guinea where hyperendemic 
malaria is reported.^ Malaria, suspected of being a cofactor, may contribute to 
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immunosuppression and foster enlargement of the pool of EBV-transformed cells. 
Over 95% of BL tumor cells contain copies of the EBV genome^^^'� whereas in 
other parts of the world, only about 20% of BL cells contain EBV DNA/^^ It is 
speculated that EBV may be involved at an early stage in BL by immortalizing B 
> 
cells. EBV manifests a distinct pattem of latency within the BL cells where only 
EBNA 1 is expressed.i33' i34 j^ addition, BL cells contain characteristic chromosomal 
translocations from chromosome 8 to chromosome 14，2 or 22 which involves 
immunoglobulin genes and also results in the deregulation of expression of the c-
myc proto-oncogene. 
1.6.3 Nasopharyngeal carcinoma (NPC) 
Nasopharyngeal carcinoma is very common among populations in southern 
China, areas include Canton, Hong Kong and Taiwan. Development of this 
undifferentiated carcinoma of nasopharyngeal epithelium strongly associated with 
EBV infection since EBV DNA is universally detected in NPC cells and three latent 
antigens are consistently expressed. High titers of antibody to the lytic cycle 
antigens are detected in NPC patients and in particular, IgA antibodies to these 
antigens are used for the early diagnosis and prognosis ofNPC. In addition to EBV, 
there are also genetic and environmental factors contributing to the initiation and 
progression ofNPC. Further details regarding NPC will be discussed later. 
1.6.4 Hodgkin's disease (HD) 
While high incidence ofBL and NPC are limited to certain geographical areas, 
Hodgkin's lymphoma is more widespread and has an incidence of 2-4 per 100,000 in 
1 8^ 
westem Europe and the USA. Recent data suggested the involvement of EBV in 
the pathogenesis of HD in a high proportion of cases, where the malignant cells 
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including the Reed-Stemberg cells contain the EBV genome in up to 50% ofcases in 
the Western countries/^^' ^^ ^ HD resembles NPC in that both follow the same pattern 
oflatency where EBNA 1，LMP 1 and LMP 2 are expressed in the cancer cells.^^^ 
• * 
1.7 Immune response to EBV infection 
1.7.1 Humoral Immune response 
Antibodies produced during EBV-induced infectious mononucleosis are 
directed against viral antigens in addition to unrelated antigens such as those on 
horse and sheep red blood cells. These antibodies are referred to as heterophile 
antibodies which are mainly IgM which do not cross-react with other EBV-specific 
antibodies.9i Heterophile antibodies are used for the diagnosis of EBV infection in 
some laboratories but the presence of these antibodies are neither indicative of 
current or past infection and does not provide any information concerning the stage 
of pathogenesis. Neutralizing IgG antibody is also generated against gp350/220, the 
most abundant viral protein expressed in the plasma membrane of lytically infected 
cells.93' 94 This specific antibody is protective to EBV infection, and mediates 
complement fixation and antibody-dependent cellular cytotoxicity.^^ Other specific 
antibodies against EBV produced will be discussed in section 1.9. 
1.7.2 Cellular Immune response 
Cellular immune response is effective for eliminating latently infected 
peripheral B lymphocytes. EBV elicits a strong HLA class !-restricted CTL response 
in the majority of infected individuals. This response is believed to play an 
important role in controlling the vims both during primary infection and in the long 
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term carrier state/^^ During the acute phase of infectious mononucleosis, the 
atypical lymphocytes observed are predominantly activated CD8+ T cells and 
CD16+ natural killer cells.96,97,98,99 j^ peripheral blood lymphocytes for EBV-
infected individuals are cultured in vitro, small clumps of infected B cells 
proliferate. In cultures maintained for a few more weeks these large clumps of 
BLCLs will regress due to the action of EBV-specific CTLs present in the initial 
blood.l05’106，107 
It had been shown that both T cells and natural killer cells are responsible for 
lysing specifically the EBV-infected B cells^^ '^ ioi thus reducing these cells from 1 in 
10 during acute IM to 1 in 10^ during convalescence/^^'^^^'^^^ However, natural 
killer cells are shown to be non-essential for the control of primary EBV infection.^^^ 
Natural killer cells do not require stimulation or previous antigen exposure but 
natural kill cells alone are not essential for the elimination of EBV-transformed 
BLCL. Nevertheless, natural killer cells contribute to immune surveillance by 
producing interferon (IFN)-a which inhibits EBV-induced B-cell proliferation and 
cytotoxic IFN-Y.i3i, i32 
EBV-specific CTLs are known to recognize HLA class !-associated peptides 
derived from EBNA2, 3A, 3B, 3C, LP, and LMP 1 and 2. Ofthese, the EBNA 3 
family is immunodominant for CTL responses over a wide range ofHLA 
backgrounds but there is as yet no published report on HLA class !-restricted CTLs 
specific for EBNA i.i09,no,m Recently, several CTL target epitopes are identified in 
LMP 2 which suggests that LMP 2 can be a potential target for CTL-based tumor 
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Latent RepHcative bnmvme 
Antigen Infection bifection Response Disease Assodation 
LYDMA + + CeUukr Prognostic of NPC treatment 
EBNA + + IgG Past infection 
EA-D 一 + IgG M,NPC 
IgA NPC 
EA-R 一 . + IgG BL, chronic infection 
VCA 一 + IgG Recent or past mfeclion 
IgM Primary infection, EM 
IgA NPC 
MA - + IgG Past infection 
NPC = nasopharyngeal carcinoona 
IM = infectious mononudeosis 
BL = Biu:kitfs lymphoma 
MA = EBV^pecdfic membrane antigen 
* 
Table 1, EBV specific antigens and immunological 
response in patients with EBV associated diseases 




1.8 Diagnosis ofEBV infection 
Epstein-Barr virus is not routinely cultured. The clinical presentation of 
infectious mononucleosis is so variable that laboratory confirmation is required. 
This rests on: a). Differential white blood cell counts and appearance of atypical 
^ 
lymphocytosis; b). the detection of heterophile antibodies, and c). EBV-specific 
antibodies. By the second and third week of the illness, the total white blood cell 
accounts for 10,000-20,000 per cubic millimeter or even higher. Lymphocytes and 
monocytes account for 60 to 80% of this number. Of these, at least 10%, and 
generally more than 25%, are "atypical lymphocytes" which persist for 2 weeks to 
several months. The atypical lymphocytes, having large pleomorphic blasts with 
deeply basophilic vacuolated cytoplasm and lobulated nuclei, are generally larger 
than normal mature lymphocytes.^^^' 14� 
Most EBV infections are diagnosed serologically. The EBV-specific antibodies 
offer a more reliable indicator of infection. Nowadays, Enzyme immunoassays 
(EIA) have become available to replace the previously employed 
immunoflorescence. Individuals with recent infection develop IgM and IgG 
antibodies to the viral capsid antigen (VCA) of EBV. Antibody of the IgG type to 
VCA is a marker of past or recent infection by EBV. Antibodies to early antigen 
(EA) may indicate current viral infection, although such antibodies are often found 
in patients with Burkitt's lymphoma or nasopharyngeal carcinoma. In addition, both 
groups of patients were shown to develop high titers of IgG antibodies against VCA. 
IgA against EBV VCA is currently used as a diagnostic marker for NPC. Finally, 
antibodies to EBNA and membrane proteins reveal past infection but not all persons 
develop antibodies to EBNA and membrane antigens. A typical pattem of antibody 
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response to EBV-specific antigens after primary infection is shown in fig. 5. Table 1 
shows the relations between immunological responses to EBV-specific antigens and 
disease manifestations. 
Other rapid diagnostic methods for EBV infection are underway such as DNA 
X hybridization and monoclonal antibody techniques.i4i'i42"3 
1.9 Treatment and prevention 
There is currently no EBV vaccine available, although potential vaccines are 
under study. Since most of the human EBV neutralizing antibody response is 
directed against gp350, therefore a subunit vaccine, based on this glycoprotein is 
undergoing trials. It has been shown to protect a portion of cottontop tamarins 
against tumor-inducing doses ofEBV/^^ 
Acyclovir is a nucleoside which has shown specific inhibitor effect on herpes 
simplex virus. It had been demonstrated that acyclovir reduced the shedding ofEBV 
from the oropharynx during the period of drug administration but it does not affect 
the number of EBV-immortalized B cells]46 Acyclovir is shown to have no effect on 
the symptoms of infectious mononucleosis and is of no proved benefit in the 
treatment ofEBV-associated lymphoma in immunocompromised patients.^^^ 
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1.10 Nasopharyngeal carcinoma (NPC) 
1.10.1 Epidemiology 
Undifferentiated nasopharyngeal carcinoma is the second most common 
� malignancy in Southern China or in emigrant Chinese from Southem China. The 
highest incidence (25-35/100,000 population per year) is observed in the Guangdong 
Provincei46 as shown in fig. 6. Despite Southem China, other high incidence areas 
include North Africa, Canada, Alaska and among Greenland Eskimos/^^ In other 
parts of the world, however, NPC is a rare tumor with an incidence rate being less 
than 1 per 100,000 persons per year/^^NPC presents in a younger population than 
other head and neck cancer sites. Its incidence increases with age, and plateaus at 50 
to 60 years. In all races, NPC is twofold to threefold more common in males.^47 
Among Chinese in Hong Kong and Singapore, NPC is the most common cancer in 
people 15 to 34 years old]48' i49 八 report has indicated that the overall standardized 
incidence rate for NPC in Hong Kong is 27.5 per 100,000 per year with a 
male/female ofll.2.^^^ 
1.10.2 Etiology 
The cause of nasopharyngeal carcinoma is mutli-factoriaL Many etiological 
factors leading to NPC have been postulated but none of them alone directly causes 
NPC. And the mechanisms of how they work in the pathogenesis of NPC are 
unknown. However, three known major factors played important roles in the 
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1.10.2.1 Environmental factor associated with NPC 
Salted fish is a popular food among the Chinese residing in the southem part of 
China, including Hong Kong. It has been implicated that salted fish is an etiological 
agent of NPC since the highest incidence of NPC has been observed in the area 
‘ populated with fishermen who consume a large quantity of salted fish in their 
diet.i5i,i52,i53,i54in additioH, 90% ofall NPC cases in Hong Kong had been suggested 
to be attributable to salted fish intake during c h i l d h o o d . i 4 6 Data suggest that 
individuals who consumed salted fish carried a relative risk of 2.6 times more likely 
to develop NPC as compared to those who did not.i55 Studies have shown that 
Cantonese style salted fish when fed to rats, produced nasal and paranasal malignant 
tumors.i59,160 xhe chemical carcinogens in such salted fish have been identified to 
be volatile nitrosamines, basically N-nitrosodimethylamine and N-
nitrosodiethylamine. i56, i57Nitrosamines, when administered orally, intravenously or 
subcutaneously, has been proven to induce squamous carcinomas, adenocarcinomas 
and other tumors in the nasal and paranasal cavities or nasophrayngeal tube of 
experimental animals. 158 
Despite salted fish as a carcinogenic factor, nitrosamines have been identified 
in some other common food such as vegetables in brine and home-made dried 
mutton preserved in olive or soya oil used in the Chinese diet.^^i other agents 
thought to be linked to the development of NPC include dust smoke, chemical 
fumes, smoke from tobacco and some Chinese herbal medicines. Moreover, it was 
noted that some kinds of vitamins and trace elements were capable of inhibiting pro-
carcinogens from converting to their active forms.i62,i63,i64 And the high incidence 
ofNPC in certain populations may be due to insufficient intake of such vitamins. 
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1.10.2.2 Genetic factors associated with NPC 
Mainland Chinese have approximately a 100-fold risk over Caucasians in 
developing NPC, although the risk ratio of NPC drops to a 20-fold increase in 
Chinese-Americans bom in the USA as compared to mainland Chinese, it is still a 
significant risk. Thus, not only environmental but also hereditary factors may be 
involved in the development of this carcinoma as seen in other cancers. Additional 
evidence relating to hereditary factors had been suggested for the human leukocyte 
antigen (HLA), a product of the major histocompatibility complex (MHC) which is 
located on the short arm of chromosome 6.i65 The expression ofHLAproducts is co-
dominant where two haplotypes constitute a genotype. Some of the haplotypes are 
identified in individuals who have increased risks of developing NPC. These are the 
A2 and Bw46 haplotypes which are common in the Chinese population.i66 in 
addition, two different haplotypes are associated with the newly diagnosed NPC 
“A2，Cwll, Bw26", and "Aw33, C3, Bw58, DR3."i65 Therefore, HLA typing may 
provide a means of screening individuals who are at risk of developing NPC. 
1.10.2.3 Association ofNPC and EBV 
EBV is strongly associated with NPC. EBV DNA is consistently detected in 
class II (partially differentiated non-keratinized carcinoma) and class III 
^)oorly/undifferentiated) NPC tumor b i o p s i e s i 6 7 , i 6 8 , i 6 9 while class I NPC 
(differentiated squamous cell carcinoma) is generally thought not to have a special 
association with EBV. However, some researchers have found EBV DNA in class I 
b i o p s i e s i 7 0 , suggesting that all histological subtypes of NPC may contain EBV 
DNA, but this conclusion remains controversial.i7i Nevertheless, the association 
between EBV and NPC is consolidated by the evidence that three latent proteins are 
regularly detected in NPC cells. They are the EBNA 1 which is expressed in all 
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undifferentiated NPC tumor cells and the two latent membrane proteins LMP 1 and 
LMP 2 which are expressed in about 50% to 70% cases whereas other EBNAs such 
EBNA 2, EBNA 3 and EBNA LP are not expressed, m，i73 These tumors are 
monoclonal with regard to EBV infection, indicating that EBV infection precedes 
‘ tumor outgrowth at the cellular level. 
The association between EBV and NPC was first revealed in serological 
studies. Patients with class II or III NPC show elevated titers of antibodies to VCA, 
the diffuse components of the early antigen complex (EA-D) and to the vims-
encoded DNase and thymidine kinase enzymes.i^^ xhe most striking feature is that 
most of the NPC patients mount a significant IgA response which may be detected at 
a 10-fold higher concentration than that in control, non-NPC pa t i en t s . ^^s Such IgA 
response has not been noted in other EBV-associated diseases except during the 
acute phase of EBV i n f e c t i o n . i 7 5 The antibody titer of anti-VCA IgA correspond 
well to the tumor load and was as a prognostic marker for tumor regression or 
recurrence. Moreover, rises in anti-EA titer precede the onset of NPC by 2-3 
years.i76 As a result, the close association between the EBV and NPC makes the 
serological detection of VCA and EA-D antibodies an useful tool in the diagnosis 
and prognosis ofNPC. 
1.10.3 Diagnosis ofNPC 
The early symptoms ofNPC are very often obscure and tend to be ignored by 
the patient. Consequently initial presentation is always delayed until the tumor is at a 
relatively advanced stage. NPC is a rapidly growing tumor with a tendency to 
metastasize early to the lymph nodes of the neck and also to distant sites such as 
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bone, liver and lung. No survivors live for more than 5 years if distant metastases 
are present or occur during the course of treatment. Therefore the early diagnosis of 
NPC is critical. As mentioned before that NPC patients usually have elevated levels 
of IgA antibody to the two lytic proteins VCA and EA. Comparing the specificity 
‘ and sensitivity of IgA anti-VCA and IgA anti-EA, the former appears to be more 
sensitive but less specific marker than the latter. Such serological characteristics are 
currently used routinely in screening patients for the early diagnosis ofNPC.i77 
Other diagnostic methods include nasopharyngoscopy, computerized tomography 
(CT) scanning, magnetic resonance imaging (MRI) or biopsy taken from 
nasopharynx ifrequired. 
Recent investigations have proposed PCR screening of metastatic unknown 
primary carcinomas to the neck of EBV capsid DNA as a molecular marker of NPC 
in the absence of biopsy-confirmed NPC in any primary s i t e . i 7 8 in addition, EBV 
viral load in serum had been suggested as diagnostic and prognostic markers for 
NPC using realtime PCR t e c h n o l o g y . i 9 i 
1.10.4 Treatment 
Currently, radiation therapy is the mainstay of treating NPC. Radiation therapy 
yields promising results especially when NPC is diagnosed in an early course. 
Surgical removal together with radiation therapy could result in over 50% patients 
with a 5-year survival. Chemotherapy, using cisplatinum, has also been used to treat 
advanced and metastasized NPC with best results observed in lung and liver. 
However, the overall cure rate for NPC is approximately less than 10% due to the 
late diagnosis of the disease. Combining radiation therapy and chemotherapy was 
investigated which may give better survival b e n e f i t s J 7 9 
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1.11 Objective ofthe Project 
EBV latent membrane protein 2 (LMP 2) is consistently expressed in 
nasopharyngeal carcinoma cells but how this protein participates in oncogenesis is 
yet unknown. Therefore, the main aim of this study is to clone the LMP 2 gene from 
•% 
EBV isolated from a Chinese NPC patient followed by DNA sequencing. The results 
ofDNA sequencing and the resulting amino acid sequence will then be compared to 
that of the standard EBV strain so as to observe, if any, genotypical or phenotypical 
changes. In addition to DNA sequencing, further analysis on hydrophobicity, 
secondary structure and isoelectric point of the LMP 2 will be conducted. Coupling 
these results with that from sequencing will provide information on whether the 
epitopes of LMP 2 expressed in NPC cells will be altered, thus resulting in a 
different pattem of immune response elicited against this protein. In addition, since 
recent researches emphasize on the efficacy ofEBV LMP 2 cytotoxic T lymphocytes 
(CTL)-based therapy, it is important to know whether the proposed EBV LMP 2 
CTL epitopes may present with specific differences in NPC patients. 
On the other hand, specific differences in the sequence of LMP 1 gene 
expressed in NPC cells had been identified previously when compared to that of the 
standard strain. A 30 bp deletion at the carboxyl terminus is consistently detected in 
most ofthe NPC biopsy specimens in Hong Kong.^ ^^ Such mutational changes may 
contribute to the development ofNPC. It is the objective of this study to examine the 
diversity and changes associated with LMP 2 gene. 
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Chapter 2 Materials and Methods 
， 2.1 EBV-containing cell cultures 
Three cell lines, B95-8, Raji and CB 14022, were used as sources of EBV 
mRNA. The B95-8 and Raji cell lines were obtained from the Tissue Culture Lab., 
Dept. ofMicrobiology, PWH, Shatin, Hong Kong. The cell lines were removed from 
liquid nitrogen where they were originally stored, and were plunged into a 37°C 
water bath. Maintenance and subculture of these cell lines were done as reported.^^^ 
After the cultured cells had defrosted, they were transferred to 15ml-centrifuge 
tubes. Nine ml ofRPMI (GIBCO BRL) supplemented with 15% fetal calf serum, 
200 mM glutamine, 7.5% sodium bicarbonate and HEPES were added slowly to the 
cells. The tubes were centrifuged for 1500 rpm for 5 minutes and the supernatant 
was discarded afterwards. The cells were resuspended in 5 ml 15% RPMI and 
2 
transferred to a 25 cm tissue culture flask. Thereafter, the flasks containing the cell 
lines were placed upright with loosened caps in a 37�C, 5% CO2 incubator (Forma 
Scientific). The volume of the culture was doubled every 2 to 3 days by adding 
RPMI with 15% fetal calf serum. Until the volume reached 20ml，the cultures were 
transferred to a larger 250 ml tissue culture flask. The volume was again doubled 
every 2 to 3 days and until the volume reached 50 ml, the medium was changed by 
replacing 25 ml old medium with 25 ml fresh RPMI every 3 days. When the cells 
appeared confluent or dead cells had been observed under a light microscope, the 
cells were ready to be splitted where half of the culture was transferred into a new 
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flask and 15% RPMI was added up to 50 ml. The medium of the cultures were 
changed constantly, and after subsequent splitting until four flasks of each cell lines 
were obtained, the cells were ready to be harvested. The cell lines were transferred 
to 50 ml centrifuge tubes, centrifuged at 1500 rpm for 10 minutes and the 
X 
supernatant was discarded, and washed with phosphate buffered saline (PBS). The 
washing step was repeated twice. 
The third cell line used, CB 14022, was cord blood lymphocytes transformed 
by EBV derived from a Chinese NPC patient, a generous gift from Dr. Dolly Huang, 
Department of Anatomical & Cellular Pathology, CUHK. The same protocol as 
above was used to culture and harvest the cord blood lymphocytes. 
2.2 Extraction oftotal RNA 
2.2.1 Cell lysis 
After washing, the cell pellets were resuspended in 1 ml ice-cold lysis buffer 
[0.14 M NaCl, 1.5 mM MgCl2, 10 mM Tris.Cl (pH 8.6), 0.5% NP-40 and 1000 
units/ml RNasin (Promega)] and vortexed for 10 seconds. Another 1 ml of the same 
lysis buffer supplemented with 24%w/v sucrose and 1% NP-40 was added and the 
tubes were placed on ice for 5 minutes. The mixture was then centrifuged at 5,000 
rpm (10,000g) for 20 minutes at 4�C in a RC-3B Refrigerated Centrifuge (Sorvall 
Instmments).210 
2.2.2 Protein digestion 
The upper layer was then recovered and 2 ml of proteinase K buffer [0.2 M 
Tris-Cl (jpR 7.5), 25 mM EDTA, 0.3 M NaCl and 2% w/v SDS was added and 
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proteinase K (Life Technology)] was then applied to a final concentration of 200 
^ig/ml and incubated at 37°C in an AutoBlot Hybridization Oven (BELLCO) for 30 
minutes. After incubation, the digested protein was removed by extracting once with 
phenol/chloroform. The upper aqueous phase was then recovered and 2.5 volumes 
^ 
of absolute ethanol were added and mixed by inverting the tubes. The tubes were 
then stored at -20°C overnight. 
2.2.3 DNA Digestion 
The proteinase K digested mixture was centrifuged at 3000 rpm at 0°C. The 
supernatant was discarded and the pellet containing nucleic acid was washed with 
75% ethanol containing 0.1 M sodium acetate (pYL 5.2). The pellet was redissolved 
in 200 i^l of 50 mM Tris Cl (pR 7.5) and 1 mM EDTA. The solution was transferred 
to microcentrifuge tubes and subsequently, 24 ^1 of MgCl2 (0.1 M) and 12 ^1 of 
RNasin (Promega) were added followed by the addition of 24 i^l of 10X DNase I 
buffer (GIBCO BRL) and 8 i^l ofDNase I (GIBCO BRL). The whole mixture was 
incubated for 30 minutes at 37°C in a heat block (Robbins Scientific). After 
incubation, EDTA and SDS were added to a final concentration of lOmM and 0.2% 
respectively. Again, the solution was extracted once with phenol/chloroform. 
2.2.4 Elution oftotal RNA 
To elute the RNA, sodium acetate (pH 5.2) was eventually added to a final 
concentration of 0.3 M and the remaining total RNA was precipitated with 2 
volumes of ethanol. After centrifuging the solution for 5 minutes at 13,000 rpm in a 
microcentrifuge (MSE) , the total RNA was eluted by adding 200 i^l of pre-warmed 
(55°C) double-distilled sterile water. 
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2.2.5 Purity and electrophoresis analysis of total RNA 
The optical densities of the extracted total RNA (1:100 dilution) and the 
negative control were measured in a Lambda Bio spectrometer (Perkin Elmer). In 
addition, the extracted total RNA and the negative control were analyzed through a 
* . 
1% agarose gel (SIGMA) with 4 i^l of ethidium bromide (GIBCO BRL) added and 
were electrophoresed in a gel tank (Pharmacia) at 100 V (ATTO) for 1 hour. 
Molecular weight markers used in gel electrophoresis were the DNA fragment of 
^X174 digested by HaeIII (GIBCO BRL) and X DNA digested by HindIII 
(Pharmacia), abbreviated as c|)X174+A,, 
2.3 First strand cDNA synthesis 
The following procedures were carried out according to the protocol of the first 
strand cDNA synthesis Kit by GIBCO BRL. 
One \Ji\ of eluted total RNAwas mixed with 1 ^1 of Oligo (dT) (500 mg/ml) and 
10 i^l of sterile distilled water. The mixture was heated to 70°C for 10 minutes and 
immediately chilled on ice. Next，4 i^l of 5X first strand buffer, 2 i^l of O.lM DTT 
and 1 ^1 of 10 mM dNTP were added and incubated at 42°C for 2 minutes. One i^l of 
Superscript^^II was then added and mixed. The mixture was incubated at 42°C for 
50 minutes and the reaction was inactivated by heating to 70°C for 15 minutes. The 
last step was to add 1 i^l (2 units) of E.coli RNase H and incubated at 37°C for 20 
minutes. The newly synthesized cDNA was ready for PCR. Reagent control was 
prepared by the same procedure and sterile distilled water was added instead of 
RNA. 
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2.4 PCR amplification ofLMP2 cDNA 
The PCR were carried out in 200 ^1 reaction tubes according to the following 
conditions: 
� 1 OX OptiBuffer™ (BIOL][NE) 5.0 ^1 
MgCl2(50mM) 1.5 i^l 
dNTP (5 mM) 2.0 i^l 
BIO-X-ACT™ Taq DNA Polymerase (4 u/^l) (BIOLmE) 0.5 i^l 
Sterile distilled water 36 i^l 
LMP2A>/B-specific forward primer^ (0.01 nmol/^i)! 2.0 i^l 
) 
LMP2-specific reverse primer (0.01 nmol/^1) 2.0 ^1 
cDNA 1.0 i^l 
Final Volume: 50 1^ 
Table 2. Reagents used in amplifying the EBV LMP 2A and LMP 2B cDNAs. 
The following is a schematic picture showing the locations of the primers on the 
LMP 2 cDNA and the directions of nucleotide synthesis. 
lbp 421bp Negative strand 2007bp 
5' — f n — . 3, 
2AF 2BF  
^ 2R 3, L _ J 5, 
Positive strand 
^LMP2A-specific forward primer (2AF): 5'-AAT CCC TCT CGC CTT G-3' 
LMP2B-specific forward primer (2BF): 5'-TAT GAA TCC AGT ATG CCT G-3' 
^MP2-specific reverse primer (2R): 5'-GCA CAT TGG GTT TAT TGT AGT-3' 
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Primers were designed from the program DNASIS and manufactured GIBCO 
BRL. Criteria included: 20-25 bp long, GC content<65% and forming least 
secondary structure. 
The following amplification program was used: initial denaturation at 94°C for 
5 min., 30 cycles of denaturation at 94�C for 1 min.，annealing at 63�C for 1 min. 
� 
and extension at lTC for 1.5 min. followed by 1 cycle of final extension 72°C for 
10 min. Each reaction was carried out in a 0.5 ml reaction tube and mn in a PCR 
machine. 
Controls: 
1. PCR reagent control: it was done using the same procedure as above except that 
sterile distilled water was added instead ofcDNA. 
2. cDNA reagent control: it was done using the same procedure as above except that 
reagent control from 2.3 First Stand cDNA Synthesis was added instead of cDNA. 
PCR mixtures were analyzed by eletrophoresis through a 1% agarose gel. 
Loading buffer and gel tank used were from Pharmacia. PCR reagent control and 
cDNA reagent control were also applied to the gel. Markers used were again 
(|)X174+X. 
2.5 Isolation ofthe PCR amplified LMP 2 cDNA 
The agarose gel was placed on an ultra-violet transilluminator OJ^ltra-Violet 
Products, Inc.) in order to visualize the DNA bands with ethidium bromide added. 
Using a clean razor blade, desired DNA band was excised as close to the DNA band 
as possible and cut into several smaller pieces and transferred to the pre-weighted 
1.5 ml microcentrifuge tubes. The weights of the microcentrifuge tubes together 
with the gel slice were then recorded. The actual weight ofthe gel slice was obtained 
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by subtracting the weight of the empty microcentrifuge tube from the total weight. 
The weight of the gel slice was adjusted to 300 mg as close as possible. 
2.6 Purification of the PCR amplified LMP 2 cDNA 
The following procedures were carried out according to the protocol of the 
GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia Biotech). 
Three hundred i^l of Capture Buffer (Buffered solution containing acetate and 
chaotrope) was added to the gel slice and mixed by vortexing. The mixture was 
incubated at 60°C until the agarose gel completely dissolved. The sample was 
transferred to a GFX Column (MicroSpin columns pre-packed with a glass fiber 
matrix) which was placed in a Collection Tube (2ml capless microcentrifuge tubes) 
and incubated at room temperature for 1 minute. The sample was then centrifuged 
for 30 seconds at 13,000 rpm in a microcentrifuge. The flow-through was discarded 
and the GFX Column was placed back into the Collection Tube. 500 i^l of Wash 
Buffer [Tris-EDTA buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA). 48 ml of 
absolute ethanol had to be added before first use] was then added to the column and 
centrifuged for 30 seconds. The collection tube together with the flow-through were 
discarded and the GFX Column was transferred to a clean 1.5 ml microcentrifuge 
tube. For the elution ofDNA, 50 i^l of pre-warmed sterile distilled water was applied 
to the GFX Column and incubated at room temperature for 1 minute. The purified 
DNA was finally collected by centrifuging the sample at 13,000 rpm for 1 minute. 
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2.7 Confirmation ofthe PCR amplified cDNA 
2.7.1 Nested PCR 
A set of internal primers designated as "1^ ^ reverse primer (lR)" and "2"^ 
, forward primer (2F)" was manufactured by GIBCO BRL so that the LMP2A;^B 
(2AF/2BF)-forward primer and the 1^^ reverse primer together amplified the first-
half portion ofLMP2A and LMP2B cDNAs whereas the 2"^ forward primer and the 
LMP2-specific reverse primer (2R) together amplified the second-half portion of 
LMP2A and LMP2B cDNAs. 
The PCR aiming to amplify the first-halfportion of LMP2A and LMP2B cDNA 
were carried out in 200^1 reaction tubes according to the following conditions: 
10X OptiBuffer™ (BIOUNE) 2.5 i^l 
MgCl2 (50 mM) 0.75 i^l 
dNTP (5 mM) 1.0 i^l 
BIO-X-ACT™ Taq DNA Polymerase (4 u/^l) (BIOUNE) 0.25 ^1 
Sterile distilled water 18 ^1 
LMP2A-specific forward primer (0.01 nmol/^il) 1.0 ^1 
1 st reverse primer^ (0 • 01 nmol/^il) 1.0 ^1 
Purified PCR products (LMP2A7B cDNA) 0.5 i^l 
Final Volume: 25 ^1 
L ^ ^ ^ = ^ = = ^ ^ ^ = ^ _ ^ ^ = = ^ _ _ _ = 
Table 3. Reagents used in nested PCR aiming at amplifying the first half 
portion of EBV LMP 2A cDNA. 
42 
Materials & Methods 
The same conditions were used for the PCR which aimed to amplify the 
second-half portion ofLMP2A and LMP2B cDNA except that the primers used were 
2"d forward primer and LMP2-specific reverse primer. The sequences of the 1^^ 
reverse primer (lR) is 5'-AAG TGT CCA TAG GAG CAT-3' whereas the 2"^ 
� forward primer (2F) is 5'-GTG GTT CTC CTG ATT TGC-3'. Primers were 
designed with the software program DNASIS (Hitachi). The following is a 
schematic picture showing the locations of the primers on the LMP 2 cDNA and the 
directions of nucleotide synthesis. 
1062 bp 
Negative strand 
lbp 421bp . 2007bp 
5’ — p ~ i — r ^ ^ ~ ~ ~ i ~ ~ T " ^ ^ ^ ~ ^ ^ ~ ~ " 3， 
2AF " • 2BF 广 2F • 
^ lR ^ 2R 3, U a _ _ i 5, 
Positive strand • 
參 
參 
The following amplification program was used: initial denaturation at 94^C for 
5 min., 20 cycles of denaturation at 94°C for 1 min., annealing at 64°C for 1 min. 
and extension at 72°C for 1.5 min. followed by 1 cycle of final extension 72°C for 
10 min. 
PCR reagent control: it was done using the same procedure as above except that 
sterile distilled water was added instead of purified PCR products. 
PCR mixtures and reagent control were analyzed by eletrophoresis through a 
1% agarose gel. Markers used were again (pG74+X. 
43 
Materials & Methods 
2.7.2 Restriction enzyme digestion 
The purified LMP2A & 2B cDNA were digested with restriction enzymes Ncol 
and Hincll according to the following conditions and incubated at 37°C overnight. 
� 
10X Buffer 2^tl 
Ncol /Hincll restriction enzyme 1 p,l 
Purified PCR products (LMP2Ay^2B cDNA) 5 i^l 
Sterile distilled water 12 ^1 
Final Volume : 20 [d 
Table 4. Components of restriction enzyme digestion 
Digestion enzymes: Ncol: Amersham, 10 U/^il and Hincll: GIBCO BRL, 10 U/^il 
Restriction enzyme-digested PCR products and negative controls were 
analyzed by eletrophoresis through a 1% agarose gel. 
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2.8 Ligation of insert LMP2 cDNA with vector 
The following procedures were carried out according to the protocol of the � 
pGEM —T Easy Vector Systems Technical Manual, Promega. 
‘ The ligation reactions were set up as below and incubated at 4 °C ovemight. 
Standard Positive Background 
Reaction Control Control 
T4 DNA Ligase 10X Buffer 1 ^1 1 ^1 1 ^1 
PGEM-T Easy Vector (50 ng) 1 ^1 1 ^1 1 ^1 
PCR product 2 ^1 ---- ----
Control Insert DNA ---- 2 ^1 ---_ 
T4 DNA Ligase (3 Weiss units/^il) 1 [i\ 1 i^l 1 ^1 
Deionized water 5 p,l 5 i^l 7 ^1 
Total Volume: lO^il lO^il 10^1 
Table 5. Components of ligation reactions. 
2.9 Transformation of competent cells JM109 
The following procedures were carried out according to the protocol of the � 
pGEM —T Easy Vector Systems Technical Manual, Promega. 
Two i^l of each ligation reaction were added to sterile 1.5 ml microcentrifuge 
tubes on ice. Another tube was also set up with 0.1 ng uncut pUC18 (American Type 
Culture Collection) added which acted as the transformation control. Tubes of frozen 
JM109 High Efficiency Competent Cells (Promega) were allowed to thaw for 5 
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minutes. Then 50^il of cells were added to each microcentrifuge tubes prepared 
before. For the transformation control, 100 pl of cells were added instead of adding 
50 ^il. The cells were placed on ice for 20 minutes with gentle flicking intermittently. 
The cells were then heat shocked for 50 seconds in a water bath at exactly 42°C. The 
� 
cells were immediately returned to ice for another 2 minutes. Nine hundred and fifty 
i^l of SOC medium at room temperature were then added to the tubes. For the 
transformation control tube, 900 ^1 of SOC medium were added instead. All the 
tubes were incubated at 37°C for 1.5 hours on a shaking platform (150 rpm). 
One hundred and fifty pl of each transformation culture was plated onto 7 LB 
plates^ with ampicillin/IPTG/ X-gal. For the transformation control, a 1:100 dilution 
with SOC medium was used for plating. All the plates were incubated at 37°C 
ovemight. 
Preparation of SOC medium: 
2.0g Bacto®-Tryptone 0.25 ml 1MKC1 
0.5 g Bacto®-Yeast Extract 1 ml 2M glucose, filter-sterilized 
1 ml 2M Mg2+ stock (lM MgCl2.6H2O/lM MgSO4 7H2O), filter-sterilized 
1 ml lM NaCl 
Bacto®-Tryptone, Bacto®-Yeast Extract, NaCl and KC1 were added to 97 ml sterile 
distilled water and stirred to dissolve, autoclaved and cooled to room temperature. 2 
2 _ | _ 
M Mg stock and 2M glucose were added next. Sterile distilled water was then 
added up to 100 ml. The complete medium was filtered through a 0.2 i^m filter. 
Preparation ofLB plates with ampicillin/IPTG/X-gal: 
1 L of LB medium was added with 15 g agar, autoclaved and allowed to cool. 
Ampicillin was added to a final concentration of 100 ^ig/ml. IPTG and X-gal were 
added to final concentrations of 0.5 mM and 80 ^ig/ml. 
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2.10 Screening of the recombinant clones 
The LB plates (ampicillin, IPTQ X-gal added) were observed. Those having 
white colonies were picked and the white colonies were innoculated separately and 
� streaked out onto LB plates with ampicillin. The plates were incubated at 37°C 
overnight. 
2.11 Small scale purification of plasmid DNA 
The following procedures were carried out according to the protocol of 
QIAprep Spin Miniprep Kit Protocol. 
Each single colony on the LB plates was innoculated into 5 ml LB broth with 
ampicillin added (100 ^g/ml). The broth was then incubated at 37°C overnight with 
constant shaking (150 rpm). 
After incubation, the broth was centrifuged and the supernatant was discarded. 
The bacterial cells were resuspended in 250 ^1 of buffer P1 and transferred to 
microcentrifuge tubes. Two hundred and fifty i^l ofbuffer P2 were added and mixed 
by inverting the tubes 4 to 6 times. Then 350 ^1 of buffer N3 was added and the 
tubes were immediately but gently inverted 4 to 6 times to mix. The tubes were 
centrifuged for 10 min. in a microcentrifuge at 13,000 rpm. The supematants were 
transferred to the QIAprep Spin Columns which were previously placed in 2-ml 
Collection Tubes. The Columns were centrifuged for 50 s and the flow-through was 
discarded. The QIAprep Spin Columns were washed by adding 0.5 ml buffer PB and 
centrifuged for 50 s. The Columns were again washed by adding 0.75 ml buffer PE 
and centrifuged for 50 s. The flow-through was discarded and the columns were 
47 
Materials & Methods 
centrifuged for another 2 min. The columns were transferred to 1.5-ml 
microcentrifuge tubes. Lastly, 50 ^il of pre-warmed sterile-distilled water was added 
to elute the D N A and centrifuged for 1 min. 
� 
2.12 Determination of the size ofthe insert DNA 
The freshly prepared plasmid D N A was digested with EcoRl. One ^1 of 10X 
buffer and 0.5 ^tl oiEcoRl (GIBOCO BRL) was added to 8.5 ^il ofeluted D N A from 
the Miniprep to make up to a total volume of 10 fol in 1.5 ml microcentrifuge tubes. 
The mixtures were incubated at 37°C ovemight. 
Before performing a gel electrophoresis analysis, the ovemight reaction 
mixtures were subject to 65°C for 2 minutes. The digested and non-digested (eluted 
D N A from Miniprep) vectors were both analyzed by electrophoresis through a 1% 
agarose gel. Markers used were again c|)X174+A,. 
2.13 DNA sequencing 
2.13.1 The Cycle Sequencing Reaction 
The method employed in sequencing is based on the Sangers-Coulson chain 
termination method. The following procedures were carried out according to the 
cycle sequencing protocol of SequiTherm E X C E L ™ II Long-Read™ D N A 
Sequencing Kit-ALF™ (Epicentre Technologies). 
For each template, four O.5ml-microcentrifuge tubes A, T, G or C were labeled 
and placed on ice. To each tube, two ^ il of each SequiTherm EXCEL II Long-Read 
Termination Mix A, T, G and C were added to each labeled tube respectively. 
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In a 0.5 ml-microcentrifuge tube labeled "Premix," the following components 
were added to a final volume of 17 ^ il: 
7.2 ^ 1 of SequiTherm EXCEL II Sequencing Buffer 
2 pmol of Cy5-labeled primer 
、 50-250 finoles ofDNA template 
deionized water to 16 ^ 1 
1 ^il SequiTherm EXCEL II D N A Polymerase (5 U/^ il) 
Forward (F，F1, F2, F3, F4, F5 and F6) and reverse (R, R1, R2, R3, R4, R5 and R6) 
primers were designed from the program DNASIS according to the sequences of the 
pGEM-T® Easy Vector and the EBV-LMP2 gene (accession no.: Y00835). The 
primers were manufactured by Genosys Biotechnologies (Europe) Ltd. 
The sequences of the primers were as follows: 
F : 5'-CAG G G T TTT C C C A G T C A C GAC-3' 
F1 : 5'-AAG TCT GTA CTT G G G ATT GCA-3' 
F2 : 5'-ACT G C G GTT G T C A C T TTC TTT-3' 
F3 : 5'-TTG G A G C T G T A A C T G T G G TTT C-3' 
F4 : 5'-AAA CTT C A A G A G TTT A A G C A G C-3' 
F5 : 5,-CTG ATT TTC CTC ATT G G C TTT G-3 ’ 
F6 : 5'-TCA CTT TGT A C A G A C TTT TGG-3' 
R : 5'-AGC G G A T A A C A A TTT C A C A C A GG-3 ‘ 
R1 : 5'-GTG TAT G C A TAG TCT G G A A G G T-3' 
R2 : 5'-ATC T G G T G G G C A TTC TTT ATA C-3' 
R3: 5'-TTC A G T G C T G C T T A A A C T CTT-3, 
R4 : 5'-AGT A G C A G C A G C GTC ATG G A A A-3' 
R5 : 5'-GCA AAT T G C A A A G A A A G T G A C A-3 ‘ 
R6 : 5,-CGT CAT TCC C G T C G T GTT GCAA-3' 
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The following is a schematic picture showing the locations of the primers on 
the L M P 2 c D N A and the directions of nucleotide synthesis. 
LMP 2 cDNA 
‘ 308bp 618bp 868bp 1196bp 1434bp 1709bp 
V ~ ~ n ~ ~ r ~ r ~ T ~ n — n n — n n — p ^ — | ^ — v 
F1 F2 F3 F4 F5 F6 
• 
< ——： ； ；    
R6 R5 R4 R3 R2 R1 
5, _ J 1—^ L - ~ J 1—^ l ~ ~ " l L«"~^  1— 3， 
1662bp 1359bp 1099bp 783bp 434bp 135bp 
*Primers F and R were located on the pGEM T-Easy Vector and were therefore not shown 
in the above diagram. 
The amount of D N A template used depends on the measured O.D.260 of the 
eluted D N A from Miniprep procedure. Four ^il of Premix were added to each of the 
four tubes of Termination mix A, T, G, C respectively and mixed thoroughly by 
vortexing. Each tube was overlayed with mineral oil, mixed and centrifuged briefly. 
The following amplification program was used: Initial denaturation at 95°C for 5 
min., 30 cycles of denaturation at 95°C for 30 s, annealing at 56^C for 30 s and 
extension at 72°C for lmin. followed by 1 cycle of final extension 70°C for 5 min. 
After the reaction had completed, 3 ^ 1 of stop/loading Buffer was added to each 
tube. The tubes were vortexed, centrifuged briefly and heated to 95°C for 3 minutes. 
The tubes were placed on ice immediately after the heating step. The samples were 
then ready for eletrophoresis analysis. 
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2.13.2 Preparation of the acrylamide gel and TBE buffer 
A total of2 liter 0.6X TBE buffer was required. This was obtained from mixing 
120 ml 10X TBE buffer with 1880 ml sterile distilled-water. 10X TBE buffer was 
prepared as follows: 242,28 g ofTribase, 102,64 g ofBoric acid and 7,44 g ofEDTA 
<» 
were weighed out. Then 1.9 liter of sterile distilled-water was added and dissolved 
with a magnetic stirrer. After the solution had dissolved, the magnetic stirrer was 
removed and sterile distilled-water was subsequently added to 2.0 liters. The 
solution was finally filtered through a 0.45 ^ im filter (Millipore HV). 
The gel solution used was Gene Page Plus 6% (Amresco) to prepare a 0.5 m m 
gel. The gel solution was originally stored at 4°C and allowed to come to room 
temperature for about 15 minutes before use. The cap of the gel bottle was 
unscrewed and a Polymerization Catalyst tablet and a Polymerization Initiator tablet 
(provided by Amersco) were placed into the solution and the cap was replaced. The 
bottle was gently swirled for 1 minute to start the polymerization of the gel. The gel 
solution was applied back and forth in an even movement along the lower edge of 
the glass plate. If bubbles were formed during the process, a pre-cleaned bubble 
chaser can be applied to the solution to remove the bubbles. The gel solution was 
allowed to set at room temperature for at least 90 minutes. 
After the gel had set, the whole gel cassette was hung into the front of the 
ALFexpress instrument. The upper and lower buffer reservoirs could be filled, each 
with 1 liter, 0.6X TBE buffer and ready for electrophoresis. 
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2.13.3 Running conditions of the electrophoresis 
The conditions for electrophoresis were set as follow: 
Voltage 1500V 
Current 60 m A 
� 
Power 25 W 
Temp erature 5 5°C 
Sampling interval 2 seconds 
Table 6. Conditions used in automated sequencing. 
Approximately 6 pl of sample was loaded into each well in the following order: 
A, C, G and T. There were a total of 40 wells which could accommodate 10 samples. 
After the samples being loaded, the electrodes, one at the top and one at the bottom, 
were placed into the each buffer reservoir. The plugs of the electrodes were inserted 
into the sockets located on the front panel. Finally the door of the instrument was 
closed and the START icon was clicked to start the program. 
2.13.4 Processing, editing and exporting the sequences 
After the run had completed, each clone sequence was analysed with the 
associated software. 
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2.14 Data analysis 
2.14.1 Sequence analysis 
The program used in sequence analysis was "Homology Search" under 
， FUNCTION, DNASIS-DB vl.l. The obtained L M P 2A gene sequences of B95-8 
cell line，designated as B95-8, and CB 14022，designated as CB 14022, were 
compared with the standard E B V L M P 2A gene sequence, designated as Y00835 
from the program E B V T E R M (Accession number: Y00835) and the exported Raji 
cell line L M P 2B sequence, designated as Raji, was compared with the standard 
E B V L M P 2B sequence Y00835 from E B V T E R M . The percent homology of each 
sequence comparison was recorded. Any sequence discrepancy was recorded as 
well. 
2.14.2 Amino acid sequence analysis 
All five D N A sequences (B98-5 L M P 2A & 2B, Raji L M P 2B and C B 14022 
L M P 2A & 2B) were translated into amino acids using the associated software. The 
amino acid sequences were compared and any difference was recorded. 
2.14.3 Protein secondary structure analysis 
After obtaining the protein sequences, they were subjected to secondary 
structure analysis using Chou and Fasman Prediction Method using the same 
software. The displayed 2-D secondary structures of different samples were 
compared manually. 
53 
Materials & Methods 
2.14.4 Hydrophobicity analysis 
Hydrophobicities of the five polypeptides were analyzed by choosing 
“Hydrophobicity Analysis", HIBIO PROSIS™. Hopp Method was employed. 
Finally, the hydrophobicitiy indexes of the various polypeptides were compared. 
� 2.14.5 Isoeletric point analysis 
By the same software, the isoelectric points of the five polypeptides were 
deduced and were then compared. 
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Chapter 3 Results 
3.1 Cell cultures 
� 
Viewed with naked eyes, the culture media for all three cell lines (B95-8, 
Raji and CB 14022) prior to harvest appeared as suspended clumps in the medium. 
Microscopically, the majority of cells were organized into big clumps with 
prominent rounded-shapes. Before harvest, cell counts were done using a 
hemacytometer and the results were as follows: 
B95-8 Raji CB 14022 
Numberofcells/ ml 2.5xl0^ 2.3xl0^ l.OxlO^ 
Table 7. Results of cell count using hemacytometer. 
For total R N A extraction of each cell line, four flasks of cell culture, each 




3.2 Extraction of total RNA 
Cells were harvested and washed with PBS by 3 times centrifugation at 
2,000 rpm for 5 minutes and total R N A was extracted as described in Chapter 2. 
� 
Optical density of RNA preparation 
The optical densities (O.D.) of the extracted R N A of the three cell lines were 
measured at wavelengths of 260 nm and 280 nm. The results were as follow: 
B95-8 Raji CB 14022 
O.D. at 260 nm 0.7719 0.8471 0.4762 
O.D. at 280 nm 0.5786 0.6238 0.3786 
Table 8. Optical densities of extracted RNA from various cell lines. 
Concentration and purity 
Concentrations of nucleic acids were calculated according to the formula: 
Concentration = [O.D. (260 nm) ] [ [0.05^g/^il] dilution factor] where dilution factor = 
100 
Purity of nucleic acids were calculated according to the formula: 
Purity = [O.D. at 260 nm] / [O.D. at 280 nm] 
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And the results were as follow: 
B95-8 Raji CB 14022 
Concentration of 335.95 423.55 238.10 
nucleic acids (^g/ml) 
� . 
Purity ofnucleic 1.3341 1.3580 1.2578 
acids 
Table 9. Concentration and purity of extracted RNA from various cell lines. 
Electrophoresis analysis 
Results of electrophoresis analysis of total R N A extraction of B95-8, Raji 
and CB 14022 cell lines are shown in fig. 7, 8 and 9 respectively. Five ^ 1 of sample 
were added to each lane. In fig. 7, Lane 1 is the lx total R N A [19.30 ^ ig/ml], Lane 2 
being diluted 10x [1.930 |^ g/ml] and Lane 3 being diluted 100x [0.1930 ^ig/ml]. 
Smear of RNAs was observed in Lane 1 and 2 whereas two distinct bands 
appeared in Lane 3 in all three samples. 
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M 1 2 3 ¾^^¾¾^¾¾^¾¾^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^¾ 
^ ^ ^ ^ B | ^ ^ ^ ^ B K ^ ^ ^ ^ ^ ^ ^ ^ M 
4361 bp [ | J ^ | ^ ^ | P | | ^ J ^ ^ J J J J ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ J M B B B I "^'" '^^^^B^^^^^B 
2322bp I M ^ B ^ ^ m ^ ^ ^ ^ H 
2027bp | ^ H ^^^tlfM ： 
i353 bp ^ m - 1 m r n ^ 
一 fci I m 
872bP ^ ^ ^ - 墨 ^ S M 
- • • 
K ^ ^ | 
Fig. 7 Total RNA extraction of B95-8 cell line. 
M: Marker, cj)174 digested by HaeIII & 人 D N A digested by HindIII 
1 : lx dilution oftotal R N A [19.30 ^ ig/ml] 
2 : 10x dilution oftotal R N A [1.930 ^ ig/ml] 




M 1 2 3 
|^2^^HI^ ^^^HI^ ^^| 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
^ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 4361 bp M H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ ^ ^ M | P ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
2322 bp ^ ^ m ^ H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
一 H V . 1 ^ V H 
^^^^^^^^^^^^K |R '^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ H^ 
1353 bp ^ ^ ^ ^ ^ ¾ , 晨 ' | ^ ^ ^ ^ H ^ H 
l。78bP i — B . 9 ^ ^ ^ 1 
_ B ^ S ： 、 ， 厘 ^ ^ ^ ^ M mmm m , ^ ^ g 603bP ^ ^ ^ ^ : H ^ ^ ^ ^ ^ H ^ ^ ^ ^ K ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
^^^^^^^^^^^1 
Fig. 8 Total RNA extraction ofRaji cell line. 
M: Marker, cj)174 digested by HaeIII & \ D N A digested by HindIII 
1 : lx dilution oftotal R N A [21.18 ^ g/ml] 
2 : 10x dilution oftotal R N A [2.118 |ig/ml] 




M 1 2 3 ^^1^1 B H | | ^ ^ 2 ^ H ^ ^ ^ H ^ H H ^ ^ ^ H ^ H ^ ^ ^ ^ ^ ^ ^ | 
4361 bp J | ^ J | | J J | | J [ ^ J ^ J 
：：^^P^^^VH 
m j i ^ ^ ^ ^ ^ E ^¾ ^ M ^ ^ ^ i i H 
| ^ ^ ^ ^ ^ p il ^ ^ B H ^ B 
'353bP | ^ S l . . M l 
io78bp | ^ ^ ^ ^ S 3 = / ‘ ^^MBM 
872 bp P | p * i ^ ^ 、邏 M | ^ ^ ^ ^ B , • mM 
H^^^^^^H^^^H 
Fig. 9 Total RNA extraction of CB 14022 cell line. 
M: Marker, cj)174 digested by HaeIII & \ D N A digested by HindIII 
1 : lx dilution oftotal R N A [11.905 ^ig/ml] 
2 : 10x dilution oftotal R N A [1.1905 ^ig/ml] 
3 : 100x dilution oftotal R N A [0.1191 ^ig/ml] 
60 
Results 
3.3 PCR amplification 
Two sets ofEBV L M P 2-specific primers flanking the 5' and 3' end of L M P 
2A and 2B were used to amplify L M P 2A c D N A (2008 bp) and L M P 2B c D N A 
(1587 bp) respectively. They were designated as 2AF, 2BF and 2R where 2AF 
� 
amplified the positive strand of L M P 2A and 2B respectively and 2R, the common 
reverse primer, amplified the negative strand as shown in the following: 
lbp 421bp Nesative strand 2007bp 
5' p * _ ^ p > _ ^ ^ ^ ^ p _ _ _ > _ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ _ ^ _ > _ 3' 
2AF ! — • 2BF • 
< 2R 3, ^ _ — ^ ^ ^ — — ^ — ^ ^ ^ ^ — — — - — — — — ^ ^ ^ — i 5， 
Positive strand 
Sequences of the primers were shown in Chapter 2 section 2.4. 
Results of the PCR amplification of the E B V L M P 2 gene from the three cell 
lines B95-8, Raji and CB 14022 are shown in fig. 10, 11 and 12 respectively. Lane 
M in all three figures is the marker D N A fragment of (j>X174 digested by HaeIII and 
\ D N A digested by HindIII. 
As shown in fig.lO, amplification of L M P 2A cDNA (2008 bp) from B95-8 
in Lane 1 showed a distinct band around the 2027 bp marker and amplification of 
L M P 2B cDNA (1587 bp) in Lane 2 showed a band which lied between 2027 bp and 
1538 bp. The PCR reagent Control (Lane 3) and cDNA reagent control (Lane 4) 
were all negative. 
In fig.ll, amplification of L M P 2B cDNA (1587 bp) from Raji cells in Lane 
1 and 2 were identical samples which gave bands sized between 2027 bp and 1353 
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bp. Amplification ofLMP 2A c D N A (2008 bp) in Lane 3 did not show visible bands 
so as the PCR reagent Control (Lane 3) and the cDNA reagent control (Lane 4). 
In fig. 12, similar results were obtained in CB 14022. 
^ . 
3.4 Isolation ofPCR amplified LMP 2 cDNA 
The weights of each sliced band were recorded. Gel slice from B95-8 
weighed 395 mg, Raji weighed 289 mg and CB 14022 weighed 290 mg. 
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M 1 2 3 4 
2027bp ^ ^ ^ ^ ^ ^ E ^ ^ ^ ^ H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
1353bp ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ H | « ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
Fig. 10 PCR amplification ofLMP 2 cDNA gene of 
B95-8 cell line. 
M: Marker, (j>174 digested by HaeIII & 1^  D N A digested by HindIII 
1 : PCR product ofLMP 2A gene 
2 : PCR product ofLMP 2B gene 
3 : PCR reagent control 
4: cDNA reagent control 
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M 1 2 3 4 
^^ ^^ K^ ^^ ^^ 5^^ '^^ S^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ |^ ^^ K||^ Km^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ |^ 
^^ ^^ l^^ ^^ j^lj^ j^^ ij^ ^^ ^^ 2^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ l^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ l^ ^ H 
gl^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^g 2027bp ^ ^ ^ ^ ^ ^ ^ ^ | ^ ^ ^ H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | ^ H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | 
i353bp f ^ ^ ^ ^ ^ | | ^ ^ m m g ^ ^ ^ ^ ^ ^ ^ M 
^^ ^^ H^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^H^^  ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ 1^ 
^^^^R^^^^^^^P^ H^^^^^^H^|^^^ H^|^^^ K^^V^^^^^^^^^^^^^ B^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^| 
^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ B^ S^ ^^ ^^ ^^ ^^ B0^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ | 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ S ^ | B H i ^ ^ ^ | H H Fig. 11 PCR amplification ofLMP 2B cDNA gene of 
Raji cell line. 
M: Marker, c|)174 digested by HaeIII & \ D N A digested by HindIII 
1 : PCR product ofLMP 2B gene 
2 : PCR product ofLMP 2B gene(same as lane 1) 
3 : PCR reagent control 
4 : cDNA reagent control 
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M 1 2 3 4 
^^^^^^^^MP^^^^^^^^^^^^^^^^^^^^^^^^^^|^^^^^^^^^^^^^^^ 
^ ^ ^ H | ^ ^ w _ ^ ^ ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ 
^^K^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^g 
^^ ^^ M|^ ^^ g^d^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ H^ ^^^^^^1 ^^^^^^^^^^^^^^^^K^^^^^^^^^^^^^^^^^^^^^^^^M 
^ ^ ^ ^ ^ ^ H l ^ ^ H H | | ^ | ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
— B ^ ^ ^ B 
2027bp ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
H ^ ^ ^ ^ S H ^ ^ H 
-p C ^ H | ^ ^ ^ | ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ m n ^ ^ H 
E ^ ^ ^ ^ ^ ^ H 
Fig. 12 PCR amplification of LMP 2 cDNA gene of 
CB 14022 cell line. 
M: Marker, cj)174 digested by HaeIII & X D N A digested by HindIII 
1 : PCR product of L M P 2A gene 
2 : PCR product ofLMP 2B gene 
3 : PCR reagent control 
4 : cDNA reagent control 
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3.5 Confirmation of the PCR amplified cDNA 
3.5.1 Nested PCR 
Internal primers 2AF, 2BF, 2F, lR and 2R were used to amplify the first half 
and second half portions of the L M P 2A and 2B cDNA as shown in the following: 
� 
LMP 2 cDNA 1062 bp 
] 421 Negative strand 2007 
5’ r ~ ~ r ~ i ~ " ^ n ~ ^ ~ ~ ~ ^ ' ~ ^ ^ r ~ ~ ~ ~ ~ ^ ^ ~ ~ ^' 
2AF |~»^ 2BF " • 2F • 
< ~~^R~~ M ~ ~ ^ ~ ~ 
3 ， _ i - ^ _ ^ ^ ^ _ L - B ^ - ^ - i ^ - ^ ^ - i - i - J - ^ 5， 
Positive strand 
Results of the nested PCR amplification of the E B V L M P 2 gene from the 
three cell lines B95-8 (fig. 13 & 14), Raji (fig. 15) and CB 14022 (fig. 16 & 17) 
were shown. Lane M in all three figures were the marker D N A fragment of cj)X174 
digested by HaeIII and X D N A digested by HindIII. 
丨 In fig. 13, amplification ofthe 1'' half of L M P 2A B95-8 cDNA (1062 bp) 
using specific primers 2AF and lR in Lane 1 showed a distinct band at about 1078 
bp and amplification ofthe 2"^  halfofB95-8 L M P 2A cDNA (945 bp) using specific 
primers 2F and 2R in Lane 2 showed a band which lied between 872 bp and 1078 
bp. The reagent control in Lane 3 did not show any observable bands. In fig. 14, 
amplification of the 1'^  half of B95-8 L M P 2B cDNA (642 bp) using specific 
primers 2BF and lR in Lane 1 showed a distinct band between the markers 603 bp 
and 872 bp and amplification ofthe 2"^  halfofB95-8 L M P 2B cDNA (945bp) using 
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Specific primers 2F and 2R in Lane 2 showed a single band which lies between 872 
bp and 1078 bp. Reagent control in Lane 3 showed no bands. 
In fig. 15, amplifications ofthe 1'' and 2"^  half ofthe Raji L M P 2B c D N A 
and the reagent control yield similar results with that ofB95-8 in fig. 14. In fig. 16 
‘ and 17, amplifications of the 1'' and 2"^  half of CB 14022 cell line L M P 2A and 
L M P 2B c D N A and the reagent control showed identical results with that ofB95-8 
in fig. 13 and 14. 
Using nested PCR method, the identity of the PCR products obtained could 
be confirmed since they were further amplified to give products of expected sizes 
using internal primers 2AF, 2BF, 2R, lR and 2F. 
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M 1 2 3 
1353 bp l ^ — ^ l ^ j j l ^ j j m i ^ ^ j ^ j j 
1078 bp | H ^ m J | f * ^ * " ^ ^ ^ J J [ ^ ^ ^ ^ ^ J 
872 bp ^ ^ H ^ | [ [ | J | ^ ^ J J J | ^ ^ ^ ^ ^ [ 
603 bp j | ^ ^ j j j [ i m m i i ^ ^ j ^ [ ^ ^ [ 
Fig. 13 Amplifications ofthe 1'^  and 2"^  portions ofthe 
B95-8 LMP 2A cDNA 
M: Marker, cj)174 digested by HaeIII & 入 D N A digested by HindIII 
1 ： Amplification of l't halfofB95-8-derived L M P 2A c D N A (1062 bp) 
2 : Amplification of2"^ halfofB95-8-derived L M P 2A cDNA (945 bp) 
3 : PCR reagent control 
M 1 2 3 
m m ^ ^ m 
E ^ ^ ^ ^ ^ H bp ^ ^ f " ^ ~ ^ ^ " ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | ^^^^^^^B|^^^^^^m|^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^B 
^ H H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 3 ^ ^ ^ ^ ^ ^ | 
bp ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ m i i i u i i ^ ^ ^ ^ ^ ^ ^ ^^^^H|^^^^^^^^^^^^^^^^^^^^H 
603 bp H R H ^ ^ ^ ^ ^ ^ 9 H H ^ ^ ^ ^ | 
^ ^ ^ ^ ^ ^ ^ ^ m m ^ ^ ^ ^ ^ ^ ^ ^ ^ g 
Fig. 14 Amplifications ofthe 1'^  and 2"^  portions ofthe 
B95-8 LMP 2B cDNA 
M: Marker, cj)174 digested by HaeIII & 入 D N A digested by HindIII 
1 ： Amplification of 1'^  halfofB95-8-derived L M P 2B cDNA (642 bp) 
2 : Amplification of2"^ halfofB95-8-derived L M P 2B cDNA (945 bp) 
3 : PCR reagent control 
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M 1 2 3 m^m 
^ ^ ^ • H 
1078 bp ^ F ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H | H H 
^^ m^iij^ iiijjj^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ n^inji^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ m^ 
^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ |^ ^^ ^^ ^^ ^^ ^^ H^|HH^ H^ 
^^ ^^ ^^ j^ ^^ ^^ ^^ ^^ ^^ [^^ ^^ [^ ^^ ^^ ^^ m^^ iji^ g^ f^_p、"'^ ^^ ^^ j^^ ^^ j^mji 
872 bp ^^^^^^^^^^^^^^^^^^|^^^^^^^^^^^^^^^^^^^^^^|^^^^^^^^^^^^^^^^^| 
^^ B^Miiti!^ilitfti"fii'1i-. <^>:^I^^^^^^^^^^^^^^^I^^^^^^^^^^^H^^^^^^^^^^^^^I^^^^^ B^^^^^^^^^^^^^^^^^^^^^^ I^ ^ ^ ^ ^ ^ K ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ K f ^ ^ ^ ^ ^ M IH^9^BH 
603 bp ^ ^ ^ ^ ^ ^ ^ | B H | | K 9 ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ m i ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
Fig. 15 Amplifications ofthe 1'^  and 2"^  portions ofthe Raji 
LMP 2B cDNA 
M: Marker, cj)174 digested by HaeIII & \ D N A digested by HindIII 
1 : Amplification of 1'^  halfofRaji-derived L M P 2B cDNA (642 bp) 
2 : Amplification of2"^ halfofRaji-derived L M P 2B cDNA (945 bp) 
3 : PCR reagent control 
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M 1 2 3 
1353 bp ^ ^ ^ P B H i i i l ^ ^ ^ ^ ^ ^ B ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
1078 bp ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ m ] ^ ^ ^ ^ ^ ^ ^ ^ | 
bp ^ ^ ^ h M m ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ m 
Fig. 16 Amplifications ofthe 1'* and 2"^  portions ofthe CB 
14022 LMP 2A cDNA 
M: Marker, (j>174 digested by HaeIII & 入 D N A digested by HindIII 
1 : Amplification of 1'^  halfofCB 14022-derived L M P 2A c D N A (1062 bp) 
2 : Amplification of2"^ halfofCB 14022-derived L M P 2A c D N A (945 bp) 
3 : PCR reagent control 
M 1 2 3 ^^^m 
1353 bp ^ ^ ^ ^ ^ ^ ^ ^ J J U i y H H ^ J J U U I 
bp ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ m m n ^ m i i m i i i i i i i m 
^ H H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ I ^ I 
啊 E^^HiiH 
603 bp ^ ^ ^ ^ ^ ^ ^ ^ ^ H H l H H ^ n ^ ^ ^ ^ ^ ^ ^ ^ ^ B | | 3 u ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | ^^^^^^^^^^^^H^^^^^^^^^|^^^^^H 
Fig. 17 Amplifications ofthe 1'' and 2"^  portions of 
the CB 14022 LMP 2B cDNA 
M: Marker, (j>174 digested by HaeIII & 入 D N A digested by HindIII 
1 : Amplification of 1'^  halfofCB 14022-derived L M P 2B cDNA (642 bp) 
2 : Amplification of2"^ halfofCB 14022-derived L M P 2B cDNA(945 bp) 3 PCR reagent c ntrol ， 
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3.5.2 Further confirmation of the identity of the LMP 2 PCR 
product using restriction enzyme digestion 
Results ofrestriction enzyme digestion ofB95-8 and Raji PCR amplified and 
purified L M P 2 cDNAs with Hincll are shown in fig. 18. Lane M in all figures was 
’ the marker D N A fragment of (j>X174 digested by HaeIII and X D N A digested by 
HindIII. Lane 1 represented the digestion of Raji L M P 2B with Hincll with two 
bands observed, one locating between 1078 bp and 1353 bp while the other between 
316 bp and 603 bp. Lane 2 represented the digestion ofB95-8 L M P 2A with Hincll. 
Two bands were observed, one locating between 1078 bp and 1353 bp while the 
other near the marker 840 bp. Lane 3 showed the digestion of B95-8 L M P 2B with 
Hincll. The results were similar to that ofRaji in Lane 1. The negative control was 
shown in Lane 4 in which no band was observed. 
Fig. 19 shows the digestion ofCB 14022 PCR amplified and purified L M P 2 
cDNAs with Hincll, Lane 1 represented the digestion of L M P 2B with Hincll with 
two bands observed, one locating between 1078 bp and 1353 bp while the other 
between 316 bp and 603 bp. Lane 2 represented the digestion of L M P 2A with 
Hincll. Two bands were observed, one locating between 1078 bp and 1353 bp while 
the other between the markers 872 bp and 603 bp. 
Results of restriction enzyme digestion ofB95-8 and Raji PCR amplified and 
purified L M P 2 cDNAs with Ncol are shown in fig. 20. Lane 1 represented the 
digestion of Raji L M P 2B with Ncol resulting in two bands, one locating between 
872 bp and 1078 bp while the other between 872 bp and 603 bp. Lane 2 represented 
the digestion of B95-8 L M P 2A with Ncol. Two bands were observed, one locating 
next to the marker 1353 bp while the other between the markers 603 bp and 872 bp. 
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Lane 3 showed the digestion ofB95-8 L M P 2B with Ncol. The results were similar 
to that ofRaji in Lane 1. 
Fig. 21 showed the digestion ofCB 14022 PCR amplified and purified L M P 
2 cDNAs with Ncol. Lane 1 represented the digestion of L M P 2A with Ncol. Two 
^ 
bands were observed, one locating next to the marker 1353 bp while the other 
between the markers 603 bp and 872 bp. Lane 2 represented the digestion of L M P 
2B with Ncol resulting in two bands, one between 872 bp and 1078 bp while the 
other between 603 bp and 872 bp. 
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M 1 2 3 
1353 bp | ^ ^ ^ ^ ^ H | | | { | | | ^ ^ ^ Q Q 9 ^ m | | | | | ^ ^ ^ ^ ^ ^ | 
^Bii^iiiimfaM^^^^^^^^^^^^^^^^B^^^^^^^^B^B^^^^^^^^^^^^^^^^^^^^B 
1078 bp ^ ^ ^ ^ ^ ^ m | | | | ^ ^ p p p | ^ m | | | | | ^ ^ ^ ^ ^ ^ ^ 
• _ _ ^ ^ ^ 




Fig. 18 Hincll digestion with B95-8 and Raji PCR amplified LMP 2 cDNAs. * 
• # 
• * « 
Lane 
M: Marker, cj)174 digested by HaeIII & 人 D N A digested by HindIII 
1 ： Digestion ofPCR amplified L M P 2B c D N A derived from Raji 
2 : Digestion ofPCR amplified L M P 2A c D N A derived from B95-8 






M 1 2 
i353 bp ^PH^^^^H^^BHIB 
^mm^^^^K^^M 
io78bp ^ K Z i m Z ^ ^ M H I I ^ H H H B B l l H - ^ 9 B 
603bP ^^^^^^^g^^^^M 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M 
^^^H^^^B^^^^^H 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ H 
Fig. 19 HinclI digestion with CB 14022 PCR 
amplified LMP 2 cDNAs. 
« » 
Lane .; 
M: Marker, c|)174 digested by HaeIII & 入 D N A digested by HindIII 
1 : Digestion ofPCR amplified L M P 2B cDNA derived from CB 14022 ^-
2 : Digestion ofPCR amplified L M P 2A cDNA derived from CB 14022 




.• . • ‘ 




M 1 2 3 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^|HHH^|^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ H^ 
1353 bp ^ ^ ^ ^ ^ ^ ^ ^ B ^ ^ ^ ^ m S u i f f j | | ^ ^ ^ ^ ^ ^ ^ M 
bp ^ ^ ^ ^ V ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | 
872 bp ^ ^ ^ ^ i ^ ^ m m i ^ ^ ^ ^ ^ ^ m i i i i i j i i i ^ ^ 
603 bp ^ ^ B 3 9 ^ ^ m ^ ^ ^ ^ ^ | | j | | | | ^ ^ ^ g | | | | | ^ ^ 
Fig. 20 Ncol digestion with B95-8 and Raji PCR 
amplified LMP 2 cDNAs. 
* 
Lane 
M: Marker, (|)174 digested by HaeIII & \ D N A digested by HindIII 
1 : Digestion ofPCR amplified L M P 2B cDNA derived from Raji 
2 : Digestion ofPCR amplified L M P 2A cDNA derived from B95-8 
3 : Digestion ofPCR amplified L M P 2B cDNA derived from B95-8 
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M 1 2 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^p 
1353 bp ^ ^ M | H i i ^ ^ m | | Q | | | ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | 
1078 bp ^ P P m ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ [ | P | ^ ^ ^ 
872 bp ^ | V m B P I ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | 
603 bp ^ ^ ^ 8 S l ^ ^ ^ ^ m P | | | | ^ ^ ^ P l | | | | | | ^ | 
Fig. 21 Ncol digestion with CB 14022 PCR 
amplified LMP 2 cDNAs. 
Lane 
M: Marker, c^ l74 digested by HaeIII & 入 D N A digested by HindIII 
1 : Digestion ofPCR amplified L M P 2A cDNA derived from CB 14022 





3.6 Transformation and screening 
After ligating the L M P 2 insert into the pGEM-T Easy vector and inserted 
into E. coli strain JM 109 using heat shock, the transformation culture together with 
controls were plated onto LB plates with ampicillWIPTG/X-gal added. Blue and 
* 
white colonies were observed on various LB plates. The results were as follows: 
B95-8 Raji CB 14022 
L M P 2A as insert W : 5 B: 53 W : 7 B:50 W : 8 B: 59 
L M P 2B as insert W : 12 B: 60 W : 10 B: 53 W : 16 B: 66 
Positive control W : 13 B: 55 
Background control No colony 
Transformation control W : 0 B: -200 
Table 10. Number ofwhite and blue colonies recorded on LB plates after the 
E. coli JM 109 being heat shocked. 
Number of white colonies and blue colonies were represented as W and B. The number of colonies 
presented above were averaged from the overall count. 
White colonies (recombinants) were picked and streaked onto new LB plates 
with ampicillin. After incubating at 37°C ovemight, the recombinants showed 
growth as a lot of white colonies were observed. 
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3.7 Extraction of plasmid DNA and digestion with 
restriction enzyme 
After innoculation of the recombinants into the LB broth and ovemight 
incubation at 37°C, the recombinants exhibited exponential growth as the broth 
� 
appeared milky. After purifying the plasmids using Miniprep, the optical densities of 
each sample were measured as follows: 
Purified plasmids Optical density at 260nm 
B95-8 L M P 2A 0.069 
B95-8 L M P 2B 0.077 
Raji L M P 2B 0.055. 
CB 14022 L M P 2 A 0.083 
CB 14022 L M P 2B 0.061 
Table 11. Optical densities of the purified plasmids. 
Results of the purified plasmids with and without digestion with EcoRl are 
shown in fig. 22-25. 
In fig. 22, lane 1 represented pGEM-T Easy vector carrying the B95-8-
derived L M P 2A insert. Lane 2 corresponded to the ^ coi^ I-digested product of those 
in lane 1. Lane 3 and 5 represented pGEM-T Easy vector carrying the B95-8-derived 
L M P 2B insert and lane 4 and 6 correspond to the digestion with EcoRl. 
In fig 23, three identical samples were shown. Odd-numbered lanes 
represented pGEM-T Easy vector carrying the Raji-derived L M P 2B insert and 
even-numbered lanes corresponded to its digestion with EcoRl. 
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M 1 2 3 4 5 6 
23130bp P | ^ | | | ^ ^ m | ^ ^ ^ | | | ^ ^ ^ 
^^^H^II I| j^]]j]^f 
4316bp ^ ^ ^ ^ l ^ ^ ^ ^ p ^ H B 
2322bp m m ^ g ^ • : . • A ^ | | J 
2027 bp ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ n i m i ^ , ' 4 i m ^ ^ m i i m 
i353 bp ^ m u ^ ^ m n i ^ i i i j ^ n i i i ^ 
^^^^^^^^^^^^^^^^^^^^^^lB^|^B^^^H 
H H H ^ ^ ^ ^ m i l l ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H I ^ 3 3 3 ^ ^ ^ ^ H 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H M ^ ^ ^ H ^^^^^^^1 
Fig. 22 Purified plasmid containing the B95-8 LMP 2 insert and 
its digestion with EcoBJL. 
• 
Lane 
M: Marker, c|)174 digested by HaeIII & 人 D N A digested by HindIII 
1 : pGEM-T Easy Vector carrying the B95-8-derived L M P 2A insert 
2 : Digestion of pGEM-T Easy Vector carrying the B95-8-derived L M P 
2A insert with EcoRl 
3 & 5 : pGEM-T Easy Vector carrying the B95-8-derived L M P 2B insert 
4 & 6 : Digestion of pGEM-T Easy Vector carrying the B95-8-derived L M P 
2B insert with EcoRl 
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M 1 2 3 4 5 6 
23130bp B ^ ^ ^ H f m ^ ^ ^ ^ ^ H ^ ^ ^ ^ ^ H ^ H ^ ^ ^ ^ | [^c^^^^^^ 
bp ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ P ^ ^ ^ ^ ^ ^ ^ P ^ ^ ^ ^ ^ ^ H 
^^^^^^^^^^^^^^^^^^^^^^^^‘ ^^ mmju^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ p^，• • -^ ^^ ^^ ^^ ^^ ^^ H^ 
^ ^ r r ^ ^ ^ ^ ^ ^ ^ H 
2322 bp ^ I g g ^ ^ ^ g ^ ^ g ^ ^ ^ g H ^ g ^ ^ ^ ^ g g l j ^ 
2027 bp ^ Q 2 | ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | ^ ^ ^ ^ B ^ ^ j ^ ^ ^ ^ M ^ B ^ J 
1353bP ^ ^ ^ ^ ^ 9 H ^ ^ | 
^ p ^ ^ ^ ^ ^ ^ m n ^ m i ^ Q ^ ^ 2 ^ ^ ^ ^ ^ ^ i ^ • H 
Fig. 23 Purified plasmid containing the Raji LMP 2B insert and 
its digestion with EcoRl. 
Lane 
M: Marker, cj)174 digested by HaeIII & X D N A digested by HindIII 
1, 3, 5 : pGEM-T Easy Vector carrying the Raji-derived L M P 2B insert 
2, 4, 6 : Digestion of pGEM-T Easy Vector carrying the B95-8-derived L M P 
2B insert with EcoRl 
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M 1 2 3 4 5 6 
� 
23130bp ^ ^ C ^ y ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^^^^^^^^^^^^^^^^^^^^^^mii^^^^^^i 
^ ^ Q j ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H | ^ ^ ^ ^ ^ ^ | ^ ^ ^ ^ ^ H 
^^^^ K^[r^^^ '^^i^^^B l^^^^^^^^^^^^^^K ^^^WT^^^B^^^^^^^^^^^^^I^^^f^w^^^^^^^^^^^^^^^^^^^M 
4361 bp m m m l | H ^ | V ^ ^ ^ ^ H 
^^^^^^^^^^^^^^^^^^^^^^^^B^ '：''：' :^ ^^ ^^ P^P|HHH^ H^^ ^^ H^|^ ^ V ‘ ^^^^^^^^^^^B^j^^^^^^Kt:-yfy.'y':. . ^^ ^^ ^^ f^ |^H^^ ^^ ^^ ^^ ^^ ^^ ^H 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ l h i ^ B ^ ^ ^ ^ ^ P ' " ^ ^ H ^ ^ ^ ^ ^ ^ H B H ^ k , : ^ ^ I ^ H M l • • j::_^ H 
2322 bp ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ m | | ^ ^ ^ ^ ^ ^ 
2027 bp ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | ^ ^ ^ ^ J ^ ^ ^ ^ ^ ^ | 
1353 bp ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | ^ 9 ^ H | | ^ H H ^ ^ ^ ^ H 
^^^^^^^^^^^^^^^^B^^^^^B^^^^^^^^m B H 
Fig. 24 Purified plasmid containing the CB 14022 LMP 2A insert 
and its digestion with EcoRl. 
Lane 
M: Marker, cj)174 digested by HaeIII & \ D N A digested by HindIII 
1, 3, 5 : pGEM-T Easy Vector carrying the CB 14022-derived L M P 2A insert 
2, 4, 6 : Digestion ofpGEM-T Easy Vector carrying the CB 14022-derived 




M 1 2 3 4 5 6 
23130bp V l P | R H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ H [ | H 
• '-^^^B[3Bin iB l 
4361 bp ^ ^ ^ j ^ j j [ j ^ j j j m u j j j j j m ^ ^ ^ j 
^^^^^^^^^^^^^^^^^^ H^' ^^^^^ ^^^ ^^^ ^^^ ^^^ ^^^ J^^^ J^^ J^^ mU^^ ^^[^^ ^^^ ^^^ ^^^ ^^^ ^^^ ^^^ ^^^ ym^jj^|P||i||[||||j||j|||^^ljjj^|^^ ^^^ ^^^ ^^^ ^^^ ^^^ J^ ^^^^^^^^^^^^^^^K J^^^jJJjUJUU|P，iiiTOBipPSjg^|^ j^gjmjJ[|jJg|pMP^^^ ^^ ^^ J^|^ J^JJ^ ^^ ^^ J^ 2322 bp ^ ^ J | ^ j | | | | ^ ^ ^ ^ ^ ^ ^ ^ ^ * " ^ ^ ^ ™ ^ J 
^^ ^^ ^^ _^^ ^^ ^^ j^^ ^^ ^^ ^^ ^^ ^^ ^^ [^[i^ mji^ [jmm^ jn^Mata<gfc^ ^^ aMA^ iii^ Bi^  «jBi& j^ i^ 
2027 bp j m m ^ ^ j ^ ^ j j m m j j u ^ j ^ ^ ^ ^ ^ ^ ^ j j 
1353 bp B W I ^ ^ ^ B ^ ^ ^ B B i f ™ 
^ ^ j j i i ^ ^ ^ ^ ^ ^ ^ ^ j i m u j i i i i i P i i j i m j u j i i i ^ ^ ^ j j i 
^S^BIBBBiB^MBWSiiiil 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ j ^ ^ ^ ^ ^ ^ m j m m 
J^ ^^ ^^ [^^ ^^ J^ ^^ ^^ ^^ ^^ ^^ J^|^ J^^ JP|J^ JJJ|||miiBMaMiJ^ B^BBBBBBBMMMHM_iiiiiil 
^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ n^imii^ 2^mm2iimim^ ^^ ^^ mi2immiumm^ ^^ f^  Fig. 25 Purified plasmid containing the CB 14022 LMP 2B 
insert and its digestion with EcoW .^ 
Lane 
M: Marker, c|)174 digested by HaeIII & 入 D N A digested by HindIII 
1, 3, 5 : pGEM-T Easy Vector carrying the CB 14022-derived L M P 2B insert 
2, 4, 6 : Digestion ofpGEM-T Easy Vector carrying the CB 14022-derived 
L M P 2B insert with EcoRl 
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In fig. 24, three identical samples were shown. Odd-numbered lanes 
represented pGEM-T Easy vector carrying the CB 14022-derived L M P 2A insert 
and even-numbered lanes corresponded to its digestion with EcoRl. 
In fig 25, three identical samples are shown. Odd-numbered lanes 
� 
represented pGEM-T Easy vector carrying the CB 14022-derived L M P 2B insert 
and even-numbered lanes corresponded to its digestion with EcoRl. 
3.8 DNA sequencing 
The L M P 2A and L M P 2B cDNA were 2008 bp and 1587 bp respectively in 
length. Both sense and anti-sense D N A strands were sequenced using the forward 
primers F, F1, F2, F3, F3, F4, F5, F6 and the reverse primers R, R1, R2, R3, R4, R5 
and R6 respectively. 
The obtained L M P 2 D N A sequences derived from B95-8, Raji and CB 
14022 are compared to that from GeneBank (DNASIS) which acted as the standard 
in this study. The results are shown in section 3.8.1. All base changes were recorded 
and were shown in table 12. The percent homologies between the standard and the 
three sources of cDNAs, B95-8, CB 14022 and Raji cell line were calculated to be 
99.8%, 99.7% and 99.4% respectively. 
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3.8.1 DNA sequence comparison 
Y00835: DNA sequence ofEBV LMP 2 derived from GeneBank 
B95-8: DNA sequence ofEBV LMP 2 derived from B95-8 cell line 
CB 14022: DNA sequence ofEBV LMP 2 derived from CB 14022 cell line 
Raji: DNA sequence ofEBV LMP 2B derived from Raji cell line 
Bold and shadowed-letter stands for base discrepancy. Arrow means specific primer used in � sequencing. Direction of arrow refers to direction of elongation 
Primer F and R are not shown since they bind to sequences of the pGEM-T Easy Vector. 
1 60 
Y 0 0 8 3 5 A A T C C C T C T C G C C T T G T T T C T C A G A G A G C A T T T C A G G C C G G T T T T G C A G T C G C T G C T G C A 
B 9 5 - 8 A A T C C C T C T C G C C T T G T T T C T C A G A G A G C A T T T C A G G C C G G T T T T G C A G T C G C T G C T G C A 
C B 1 4 0 2 2 A A T C C C T C T C G C C T T G T T T C T C A G A G A G C A T T T C A G G C C G G T T T T G C A G T C G C T G C T G C A 
R a j i  
61 120 
Y 0 0 8 3 5 G C T A T G G G G T C C C T A G A A A T G G T G C C A A T G G G C G C G G G T C C C C C T A G C C C C G G C G G G G A T 
B 9 5 - 8 G C T A T G G G G T C C C T A G A A A T G G T G C C A A T G G G C G C G G G T C C C C C p \ G C C C C G G C G G G G A T 
C B 1 4 0 2 2 G C T A T G G G G T C C C T A G A A A T G G T G C C A A T G G G C G C G G G T C C C C C T A G C C C C G G C G G G G A T 
R a j i  
121 180 
Y〇〇 835 C C G G A T G G G T A C G A T G G C G G A A A C A A C T C C C A A T A T C C A T C T G C T T C T G G C T C T T C T G G G 
B 9 5 - 8 C C G G A T G G G T A C G A T G G C G G A A A C A A C T C C C A A T A T C C A T C T G C T T C T G G C T C T T C T G G G 
C B 14 〇22 C C G G A T G G G T A C G A T G G C G G A A A C A A C T C C C A A T A T C C A T C T G C T T C T G G C T C T T C T G G G 
R a j i  
181 240 
Y〇〇 835 A A C A C C C C C A C C C C A C C G A A C G A T G A G G A A C G T G A A T C T A A T G A A G A G C C C C C A C C G C C T 
B 9 5 - 8 A A C A C C C C C A C C C C A C C G A A C G A T G A G G A A C G T G A A T C T A A T G A A G A G C C C C C A C C G C C T 
C B 1 4 0 2 2 A A C A C C C C C A C C C C A C C G A A C G A T G A G G A A C G T G A A T C T A A T G A A G A G C C C C C A C C G C C T 
R a j i  
2 4 1 300 
Y 0 0 8 3 5 T A T G A G G A C C C A T A T T G G G G C A A T G G C G A C C G T C A C T C G G A C T A T C A A C C A C T A G G A A C C 
B 9 5 - 8 T A T G A G G A C C C A T A T T G G G G C A A T G G C G A C C G T C A C T C G G A C T A T C A A C C A C T A G G A A C C 
C B 1 4 0 2 2 T A T G A G G A C C C A T A T T G G G G C A A T G G C G A C C G T C A C T C G G A C T A T C A A C C A C T A G G A A C C 
R a j i  
3 0 1 L L _ ^ 360 
Y〇0 835 C A A G A T C A A A G T C T G T A C T T G G G A T T G C A A C A C G X C G G G A A T G A C G G G C T C C C T C C C C C T 
B 9 5 - 8 C A A G A T C A A A G T C T G T A C T | G G G A T T G C A ? \ C A C G A C G G G A A T G A C G G G C T C C C T C C C C C T 
C B 1 4 0 2 2 C A A G A T C A 7 \ A G T C T G T A C T T G G G A T T G C A A C A C G A C G G G A A T G A C G G G C T C C C T C C C C C T 
Raj i ( 
R6 
3 6 1 420 
Y 0 0 8 3 5 C C C T A C T C T C C A C G G G A T G A C T C A T C T C A A C A C A T A T A C G A A G A A G C G G G C A G A G G A A G T 
B 9 5 - 8 C C C T A C T C T C C A C G G G A T G A C T C A T C T C A A C A C A T A T A C G A A G A A G C G G G C A G A G G A A G T 
C B 1 4 0 2 2 C C C T A C T C T C C A C G G G A T G A C T C A T C T C A A C A C A T A T A C G A A G A A G C G G G C A G A G G A A G T 
R a j i T 
421 480 
Y 0 0 8 3 5 A T G A A T C C A G T A T G C C T G C C T G T A A T T G T T G C G C C C T A C C T C T T T T G G C T G G C G G C T A T T 
B 9 5 - 8 A T G A A T C C A G T A T G C C T G C C T G T A A T T G T T G C G C C C T A C C T C T T T T G G C T G G C G G C T A T T 
C B 1 4 0 2 2 A T G A A T C C A G T A T G C C T G C C T G T A A T T G T T G C G C C C T A C C T C T T T T G G C T G G C G G C T A T T 
R a j i A T G A A T C C A G T A T G C C T G C C T G T A A T T G T T G C G C C C T A C C T | T T T T G G C T G G C G G C T A T T 
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4 8 1 540 
Y 0 0 8 3 5 G C C G C C T C G T G T T T C A C G G C C T C A G T T A G T A C C G T T G T G A C C G C C A C C G G C T T G G C C C T C 
B 9 5 - 8 G C C G C C T C G T G T T T C A C G G C C T C A G T T A G T A C C G T T G T G A C C G C C A C C G G C T T G G C C C T C 
C B 1 4 0 2 2 G C C G C C T C G T G T T T C A C G G C C T C A G T T A G T A C C G T T G T G A C C G C C A C C G G C T T G G C C C T C 
R a j i G C C G C C T C G T G T T T C A C G G C C T C A G T T A G T A C C G T T G T G | C C G C C A C C G G C T T G G C C C T C 
5 4 1 600 
Y 0 0 8 3 5 T C A C T T C T A C T C T T G G C A G C A G T G G C C A G C T C A T A T G C C G C T G C A C A A A G G A A A C T G C T G 
B 9 5 - 8 T C A C T T C T A C T C T T G G C A G C A G T G G C C A G C T C A T A T G C C G C T G C A C A A A G G A A A C T G C T G 
X C B 1 4 0 2 2 T C A C T T C T A C T C T T G G C A G C A G T G G C C A G C T C A T A T G C C G C T G C A C A A A G G A A A C T G C T G 
R a j i T C A C T T C T A C T C T T G G C A G C A G T G G C C A G C T C A T A T G C C G C T G C A C A A A G G A A A C T G C T G 
601 ^ ^ 660 
Y 0 0 8 3 5 A C A C C G G T G A C A G T G C T T A C T G C G G T T G T C A C T T T C T f T G C A A T T T G C C T A A C A T G G A G G 
B 9 5 - 8 A C A C C G G | G A C A G T G C T T A C T G C G G T T G T C A C T T T C T T T G C A A T T T G C C T A A C A T G G A G G 
C B 1 4 0 2 2 A C A C C G G T G A C A G T G C T T A C T G C G G T T G T C A C T T T C T T T G C A A T T T G C C T A A C A T G G A G G 
Raj i A C A C C G G T G A C A G T | C T T A C T G C G G T ^ T C A C T T T C T T T G C A A T T T G C C T A A C A T G G A G G 
R 5 
661 720 
Y 0 0 8 3 5 A T T G A G G A C C C A C C T T T T A A T T C T C T T C T G T T T G C A T T G C T G G C C G C A G C T G G C G G A C T A 
B 9 5 - 8 A T T G A G G A C C C A C C T T T T A A T T C T C T T C T G T T T G C A T T G C T G G C C G C A G C T G G C G G A C T A 
C B 1 4 0 2 2 A T T G A G G A C C C A C C T T T T A A T T C T C T T C T G T T T G C A T T G C T G G C C G C A G C T G G C G G A C T A 
R a j i A T T G A G G A C C C A C C T T T T A A T T C T C T T C T G T T T G C A T T G C T G G C C G C A G C T G G C G G A C T A 
7 2 1 780 
Y 0 0 8 3 5 C A A G G C A T T T A C G T T C T G G T G A T G C T T G T G C T C C T G A T A C T A G C G T A C A G A A G G A G A T G G 
B 9 5 - 8 C A A G G C A T T T A C G T T C T G G T G A T G C j T G T G C T C C T G A T A C T A G C G T A C A G A A G G A G A T G G 
C B 1 4 0 2 2 C A A G G C A T T T A C G T T C T G G T G A T G C | T G T G C T C C T G A T A C T A G C G T A C A G A A G G A G A T G G 
R a j i C A A G G C A T T T A C G T T C T G G T G A T G C T T G T G C T C C T G A T A C T A G C G T A C A G A A G G A G A T G G 
7 8 1 840 
Y 0 0 8 3 5 C G C C G T T T G A C T G T T T G T G G C G G C A T C A T G T T T T T G G C A T G T G T A C T T G T C C T C A T C G T C 
B 9 5 - 8 C G C C G T T T G A C T G T T T G T G G C G G C A T C A T G T T T T T G G C A T G T G T A C T T G T C C T C A T C G T C 
C B 1 4 0 2 2 C G C C G T T T G A C T G T T T G T G G C G G C A T C A T G T T T T T G G C A T G T G T A C T T G T C C T C A | C G T C 
R a j i C G C C G T T T G A C T G T T T G T G G C G G C A T C A T G T T T T T G G C A T G T G T A C T T G T C C T C A T C G T C 
841 Y1 ^ 900 
Y 0 0 8 3 5 G A C G C T G T T T T G C A G C T G A G T C C C C T C C T T G G A G C T G T A A C T G T G G T f T C C A T G A C G C T G 
B 9 5 - 8 G A C G C T G T T T T G C A G C T G A G T C C C C T C C T T G G A G C T G T A A C T G T G G T T T C C A T G A C G C T G 
C B 1 4 0 2 2 G A C G C T G T T T T G C A G C T G A G T C C C C T C C T T G G A G C T G T A A C T G T G G T T T C C A T G A C G C T G 
Raj i G A C G C T G T T T T G C A G C T G A G T C C C C T C C T T G G A G C T G T A A C T G T G G ^ T C C A T G A C G C T G 
R4 
901 960 
Y 0 0 8 3 5 C T G C T A C T G G C T T T C G T C C T C T G G C T C T C T T C G C C A G G G G G C C T A G G T A C T C T T G G T G C A 
B 9 5 - 8 C T G C T A C T G G C T T T C G T C C T C T G G C T C T C T T C G C C A G G G G G C C T A G G T A C T C T T G G T G C A 
C B 1 4 0 2 2 C T G C T A C T G G C T T T C G T C C T C T G G C T C T C T T C G C C A G G G G G C C T A G G T A C T C T T G G T G C A 
R a j i C T G C T A C T G G C T T T C G T C C T C T G G C T C T C T T C G C C A G G G 6 G C C T A G G T A C T C T T G G T G C A 
961 1020 
Y 0 0 8 3 5 G C C C T T T T A A C A T T G G C A G C A G C T C T G G C A C T G C T A G C G T C A C T G A T T T T G G G C A C A C T T 
B 9 5 - 8 G C C C T T T T A A C A T T G G C A G C A G C T C T G G C A C T G C T A G C G T C A C T G A T T T T G G G C A C | C T T 
C B 1 4 0 2 2 G C C C T T T T A A C A T T G G C A G C A G C T C T G G C A C T G C T A G C G T C A C T G A T T T T G G G C A C A C T T 
R a j i G C C C T T T T A A C A T T G G C A G C A G C T C T G G C A C T G C T A G C G T C A C T G A T T T T G G G C A C A C T T 
1021 1080 
Y 0 0 8 3 5 A A C T T G A C T A C A A T G T T C C T T C T C A T G C T C C T A T G G A C A C T T G T G G T T C T C C T G A T T T G C 
B 9 5 - 8 A A C T T G A C T A C A A T G T T C C T T C T C A T G C T C C T A T G G A C A C T T G T G G T T C T C C T G A T T T G C 
C B 1 4 0 2 2 A A C T T G A C T A C A A T G T T C C T | C T C A T G C T C C T A T G G A C A C T T G T G G T T C T C C T G A T T T G C 




Y 0 0 8 3 5 T C T T C G T G C T C T T C A T G T C C A C T G A G C A A G A T C C T T C T G G C A C G A C T G T T C C T A T A T G C T 
B 9 5 - 8 T C T T C G T G C T C T T C A T G T C C A C T G A G C A A G A T C C T T C T G G C A C G A C T G T T C C T A T A T G C T 
C B 1 4 0 2 2 T C T T C G T G C T C T T C A T G T C C A C T G A G C A A G A T C C T T C T G G C A C G A C T G T T C C T A T A T G C T 
R a j i T C T T C G T G C T C T T C A T G T C C A C T G A G C A A G A T C C T T C T G G C A C G A C T G T T C C T A T A T G C | 
1 1 4 1 1 2 0 0 
Y 0 0 8 3 5 C T C G C A C T C T T G T T G C T A G C C T C C G C G C T A A T C G C T G G T G G C A G T A T T T T G C A A A C A A A C 
B 9 5 - 8 C T C G C A C T C T T G T T G C T A G C C T C C G C G C T A A T C G C T G G T G G C A G T A T T T T G C A A A C A A A C 
, C B 1 4 0 2 2 C T C G C A C T C T T G T T G C T A G C C T C C G C G C T A A T C G C T G G T G G C A G T A T T T T G C A A A C A A A C 
R a j i C T C G C A C T C T T G T T G C T A G C C T C C G C G C T A A T C G C T G G T G G C A G T A T T T T G C A A A C A A A C 
1201 似 〉 1260 
Y 0 0 8 3 5 T T C A A G A G T T T A A G C A C C A C T G A A T T T A T A C C C A A T T T G T T CT G C A T G T T A T T A C T G A T T 
B 9 5 - 8 T T C A A G A G T T T A A G C A G C A C T G A A T T T A T A C C C A A T T T G T T C T G C A T G T T A T T A C T G A T T 
C B 1 4 0 2 2 T T C A A G A G T T T A A G C A G C A C T G A A T T T A T A C C C A A T T T G T T C T G C A T G T T A T T A C T G A T T 
Raj i T T C ^ G A G T T T ^ V G C A G C A C T G A | T T T A T A C C C A A T T T G T T C T G C A T G T T A T T A C T p L T T 
1 2 6 1 ^ 1320 
Y 0 0 8 3 5 G T C G C T G G C A T A C T C T T C A T T C T T G C T A T C C T G A C C G A A T G G G G C A G T G G A A A T A G A A C A 
B 9 5 - 8 G T C G C T G G C A T A C T C T T C A T T C T T G C T A T C C T G A C C G A A T G G G G C A G T G G A A A T A G A A C A 
C B 1 4 0 2 2 G T C G C T G G C A T A C T C T T C A T T C T T G C j V T C C T G A C C G A A T G G G G C A G T G G A A A T A G A A C A 
R a j i G T C G C T G G C A T A C T C T T C A T T C T T G C T A T C C T G A C C G A A T G G G G C A G T G G A A A T A G A A C A 
1 3 2 1 1380 
Y 0 0 8 3 5 T A C G G T C C A G T T T T T A T G T G C C T C G G T G G C C T G C T C A C C A T G G T A G C C G G C G C T G T G T G G 
B 9 5 - 8 T A C G G T C C A G T T T T T A T G T G C C T C G G T G G C C T G C T C A C C A T G G T A G C C G G C G C T G T G T G G 
C B 1 4 0 2 2 T A C G G T C C A G T T T T T A T G T G C C T C G G T G G C C T G C T C A C C A T G G T A G C C G G C G C T G T G T G G 
R a j i T A C G G T C C A G T T T T T A T G T G C C T C G G | G G C C T G C T C A C C A T G G T A G C C G G C G C T G T G T G G 
1 3 8 1 1440 
Y 0 0 8 3 5 C T G A C G G T G A T G T C T A A C A C G C T T T T G T C T G C C T G G A T T C T T A C A G C A G G A T T C C T G A T T 
B 9 5 - 8 C T G A C G G T G A T G T C T A A C A C G C T T T T G T C T G C C T G G A T T C T T A C A G C A G G A T T C C T G A T T 
C B 1 4 0 2 2 C T G A C G G T G A T G T C T A A C A C G C T T T T G T C T G C C T G G A T T C T T A C A G C A G G A T T C C T G A T T 
R a j i C T G A C G G T G A T G | C T A A C A C G C T T T T G T C T G C C T G G A T T C T T A C A G C A G G A T T C C T G A T T 
1 4 4 1 R5 1500 
Y 0 0 8 3 5 T T C C T C A T T G G C T O : ^ G C C C T C T T T G G G G T C A T T A G A T G C T G C C G C T A C T G C T G C T A C T A C 
B 9 5 - 8 T T C C T C A T T G G C T T T G C C C T C T T T G G G G T C A T T A G A T G C T G C C G C T A C T G C T G C T A C T A C 
C B 1 4 0 2 2 T T C C T C A T T G G C T T T G C C C T | T T T G G G G T C A T T A G A T G C T G C C G C T A C T G C T G C T A C T A C 
R a j i T T C C T C A T T G G C T T T G C C C T C T T T G G G G T C A T T A G A T G C T G C C G C T A C T G C T G C T A C T A C 
1 5 0 1 1560 
Y 0 0 8 3 5 T G C C T T A C A C T G G A ? y \ G T G A G G A G C G C C C A C C G A C C C C A T A T C G C A A C A C T G T A T A A A G A 
B 9 5 - 8 T G C C T T A C A C T G G A A A G T G A G G A G C G C C C A C C G A C C C C A T A T C G C A A C A C T G T A T A A A G A 
C B 1 4 0 2 2 T G C C T T A C A C T G G A A A G T G A G G A G C G C C C A C C G A C C C C A T A T C G C A A C A C T G T A T A A A G A 
Raj i T G C C T T A C A C T G G A A A G T G A G G A G C G C C C A C C G A C C C C A T A T C G C A A C A C T G ^ T A A A G A 
1 5 6 1 1620 
Y 0 0 8 3 5 A T G C C C A C C A G A T C G C C T G C C A C T T C C A C A G C A A T G G C A C G G A T G C C T G G C G C T T T G C T A 
B 9 5 - 8 A T G C C C A C C A G A T C G C C T G C C A C T T C C A C A G C A A T G G C A C G G A T G C C T G G C G C T T T G C T A 
CB 1 4 0 2 2 A T G C C C A C C A G A T C G C C T G C C A C T T C C A C A G C A A T G G C A C G G A T G C C T G G C G C T T T G C T A 
R a j i A T G C C C A C C A G A T C G C C T G C C A C T T C C A C A G C A A T G G C A C G G A T G C C T G G C G C T T T G C T A 
R2 
1621 1680 
Y 0 0 8 3 5 T G A A T T A T C C A A G A A A C C C C A C G G A G C A G G G C A A C A T T G C A G G G C T C T G T T C A C G C G A T G 
B 9 5 - 8 T G A A T T A T C C A A G A A A C C C C A C G G A G C A G G G C A A C A T T G C A G G G C T C T G T T C A C G C G A T G 
C B 1 4 0 2 2 T G A A T T A T C C A A G A A A C C C C A C G G A G C A G G G C A A C A T T G C A G G G C T C T G T T C A C G C G A T G 
R a j i T G A A T T A T C C A A G A A A C C C C A C G G A G C A G G G C A A C A T T G C A G G G C T C T G T T C A C G C G A T G 
86 
Results 
1 6 8 1 ^ ^ 1 7 4 0 
Y 0 0 8 3 5 G T C G T C A T C T G G C T C T C C T G T G T G A C C C C T C A C T T T G T A C A G A C T T T T ( ^ G C A A T G G G A G C 
B 9 5 - 8 G T C G T C A T C T G G C T C T C C T G T G T G A C C C C T C A C T T T G T A C A G A C T T T T G G C A A T G G G A G C 
C B 1 4 0 2 2 G T C G T C A T C T G G C T C T C C T G T G T G A C C C C T C A C T T T G T A C A G A C | T T T G G C A A T G G G A G C 
R a j i G T C G T C A T C T G G C T C T C C T G T G T G A C C C C T C A C T T T G T A C A G A C T T T T G G C A A T G G G A G C 
1 7 4 1 1800 
Y 0 0 8 3 5 A C A T T C C C C C C G C C T T T G G G C A C C C C A C G G G G T G C T C C C C C T G G A C A C T T A T G T T T C A A G 
、 B 9 5 - 8 A C A T T C C C C C C G C C T T T G G G C A C C C C A C G G G G T G C T C C C C C T G G A C A C T T A T G T T T C A A G 
C B 1 4 0 2 2 A C A T T C C C C C C G C C T T T G G G C A C C C C A C G G G G T G C T C C C C C T G G A C A C T T A T G T T T C A A G 
R a j i A C A T T C C C C C C G C C T T T G G G C A C C C C A C G G G G T G C T C C C C C T G G A C A C T T A T G T T T C A A G 
1801 1860 
Y 0 0 8 3 5 C A G C T C A C C T A T G G T C A C T C A G G C A C G G T C G C C C C T C C G A G T G A C C A G T C A C C T T C C A G A 
B 9 5 - 8 C A G C T C A C C T A T G G T C A C T C A G G C A C G G T C G C C C C T C C G A G T G A C C A G T C A C C T T C C A G A 
C B 1 4 0 2 2 C A G C T C A C C T A T G G T C A C T C A G G C A C G G T C G C C C C T C C G A G T G A C C A G T C A C C T T C C A G A 
Raj i C A G C T C A C C T A T G G T C A C T C A G G C A C G G T C G C C C C T C C G A G T G A C C A G T C A ^ T T C C A G A 
1 8 6 1 1920 
Y 0 0 8 3 5 C T A T G C A T A C A C T G A A T T T A G C C T G A T A T T G T C C C C C T A G C C C C G G G C C C A G C C C T C C T C 
B 9 5 - 8 C T A T G C A T A C A C T G A A T T T A G C C T G A T A T T G T C C C C C T A G C C C C G G G C C C A G C C C T C C T C 
C B 1 4 0 2 2 C T A T G C A T A C A C T G A A T T T A G C C T G A T A T T G T C C C C C T A G C C C C G G G C C C A G C C C T C C T C 
R a j i C T A T G C A T A C A C T G A A T T T A G C C T G A T A T T G T C C C C C T A G C C C C G G G C C C A G C C C T C C T C 
1 9 2 1 R1 1980 
Y 0 0 8 3 5 A G A A A A C T C T G C A T G G A G A A G C T G G A C G T G A A C C T C C C C C C C A G A C C T G T G T G C T G T A T T 
B 9 5 - 8 A G A A A A C T C T G C A T G G A G A A G C T G G A C G T G A A C C T C C C C C C C A G A C C T G T G T G C T G T A T T 
C B 1 4 0 2 2 A G A A A A C T C T G C A T G G A G A A G C T G G A C G T G A A C C T C C C C C C C A G A C C T G T G T G C T G T A T T 
R a j i A G A A A A C T C T G C A T G G A G A A G C T G G A C G T G A A C C T C C C C C C C A G A C C T G T G T G C T G T A T T 
1 9 8 1 2008 
Y 0 0 8 3 5 T A C A A A C A C T A C A A T A A A C C C A A T G T G C 
,^  B 9 5 - 8 T A C A A A C A C T A C A A T A A A C C C A A T G T G C 
‘ CB 1 4 0 2 2 T A C A A A C A C T A C A A T A A A C C C A A T G T G C 
R a j i T A C A A A C A C T A C A A T A A A C C C A A T G T G C 
87 
Results 
Source of cDNA Change Location Bas，change  
肌* Sense Strand Anti-sense strand 
1 Exon l,base 105 T — C A — G 
2 Exon 1, base 320 T~>C A~>G 
I 
B95-8 3 Exon 2, base 608 T — C A ^ G 
4 Exon 4, base 746 T~>C A — G 
5 Exon 5, base 1017 A — G T — C 
1 Exon 4, base 746 T~>C A — G 
2 Exon 4, base 836 T — G A — C 
C B 14022 3 Exon 5, base 1041 T — C A~>G 
4 Exon 7, base 1287 T — C A — G 
5 Exon 8, base 1461 C~>T G — A 
6 Exon 9, base 1725 T — G A — C 
1 Exon 2, base 462 C — G G~>C 
2 Exon 2, base 520 A — C T — G 
3 Exon 2, base615 G~>T C~>A 
4 Exon 6, base 1140 T~>C A~>G 
5 Exon 6, base 1212 A — G T — C 
Raji  
6 Exon 6, base 1224 A — T T — A 
7 Exon 7, base 1257 G — T C~>A 
8 Exon 7, base 1347 T~>C A — G 
9 Exon 7, base 1393 T~>A A — T 




3.9 Amino acid sequence homology 
The L M P 2 D N A sequences derived from B95-8, Raji and CB 14022 were 
translated into amino acid sequences and were compared to that from the GeneBank 
(DNASIS). The degrees of homology are shown in section 3.9.1. All amino acid 
� . 
substitutions were recorded and were shown in table 14. The percent homologies 
between the standard and the three cell lines B95-8, CB 14022 and Raji cell were 
calculated to be 99.4%, 99.4% and 99.2% respectively. 
Amino Acid Abbreviation Amino Acid Abbreviation 
Alanine A Leucine L 
Arginine R Lysine K 
Asparagine N Methionine M 
Aspartic Acid D Phenylalanine F 
Cysteine C Proline P 
Glutamine Q Serine S 
Glutamic Acid E Threonine T 
Glycine G Tryptophan W 
Histidine H Tyrosine Y 
Isoleucine I Valine V 
Table 13. Amino acid key 
89 
Results 
3.9.1 Amino acid sequence comparison 
Y00835: Amino acid sequence ofEBV LMP 2 derived from GeneBank 
B95-8: Amino acid sequence ofEBV LMP 2 derived from B95-8 cell line 
CB 14022 : Amino acid sequence ofEBV LMP 2 derived from CB 14022 cell line 
Raji: Amino acid sequence ofEBV LMP 2B derived from Raji cell line 
Bold and shadowed-letter stands for amino acid residue discrepancy. 
1 60 
Y 0 0 8 3 5 M G S L E M V P M G A G P P S P G G D P D G Y D G G N N S Q Y P S A S G S S G N T P T P P N D E E R E S N E E P P P P Y 
‘ B 9 5 - 8 M G S L E M V P M G A G P P S P G G D P D G Y D G G N N S Q Y P S A S G S S G N T P T P P N D E E R E S N E E P P P P Y 
C B 1 4 0 2 2 M G S L E M V P M G A G P P S P G G D P D G Y D G G N N S Q Y P S A S G S S G N T P T P P N D E E R E S N E E P P P P Y 
R a j i  
61 120 
Y 0 0 8 3 5 E D P Y W G N G D R H S D Y Q P L G T Q D Q S L Y L G L Q H D G N D G L P P P P Y S P R D D S S Q H I Y E E A G R G S M 
B 9 5 - 8 E D P Y W G N G D R H S D Y Q P L G T Q D Q S L Y | G L Q H D G N D G L P P P P Y S P R D D S S Q H I Y E E A G R G S M 
C B 1 4 0 2 2 E D P Y W G N G D R H S D Y Q P L G T Q D Q S L Y L G L Q H D G N D G L P P P P Y S P R D D S S Q H I Y E E A G R G S M 
R a j i M 
121 180 
Y 0 0 8 3 5 N P V C L P V I V A P Y L F W L A A I A A S C F T A S V S T V V T A T G L A L S L L L L A A V A S S Y A A A Q R K L L T 
B 9 5 - 8 N P V C L P V I V A P Y L F W L A A I A A S C F T A S V S T W T A T G L A L S L L L L A A V A S S Y A A A Q R K L L T 
C B 1 4 0 2 2 N P V C L P V I V A P Y L F W L A A I A A S C F T A S V S T V V T A T G L A L S L L L L A A V A S S Y A A A Q R K L L T 
Raj i N P V C L P V I V A P Y L F W L A A I A A S C F T A S V S T V V f V T G L A L S L L L L A A V A S S Y A A A Q R K L L T 
181 240 
Y 0 0 8 3 5 P V T V L T A W T F F A I C L T W R I E D P P F N S L L F A L L A A A G G L Q G I Y V L V M L V L L I L A Y R R R W R 
B 9 5 - 8 P , V L T A W T F F A I C L T W R I E D P P F N S L L F A L L A A A G G L Q G I Y V L V M | V L L I L A Y R R R W R 
C B 1 4 0 2 2 P V T V L T A V V T F F A I C L T W R I E D P P F N S L L F A L L A A A G G L Q G I Y V L V M | V L L I L A Y R R R W R 
R a j i P V T V L T A W T F F A I C L T W R I E D P P F N S L L F A L L A A A G G L Q G I Y V L V M L V L L I L A Y R R R W R 
2 4 1 300 
Y 0 0 8 3 5 R L T V C G G I M F L A C V L V L I V D A V L Q L S P L L G A V T V V S M T L L L L A F V L W L S S P G G L G T L G A A 
B 9 5 - 8 R L T V C G G I M F L A C V L V L I V D A V L Q L S P L L G A V T V V S M T L L L L A F V L W L S S P G G L G T L G A A 
C B 1 4 0 2 2 R L T V C G G I M F L A C V L V L | V D A V L Q L S P L L G A V T W S M T L L L L A F V L W L S S P G G L G T L G A A 
R a j i R L T V C G G I M F L A C V L V L I V D A V L Q L S P L L G A V T W S M T L L L L A F V L W L S S P G G L G T L G A A 
3 0 1 360 
Y 0 0 8 3 5 L L T L A A A L A L L A S L I L G T L N L T T M F L L M L L W T L W L L I C S S C S S C P L S K I L L A R L F L Y A L 
B 9 5 - 8 L L T L A A A L A L L A S L I L G T L N L T T M F L L M L L W T L W L L I C S S C S S C P L S K I L L A R L F L Y A L 
CB 1 4 0 2 2 L L T L A A A L A L L A S L I L G T L N L T T M F L L M L L W T L W L L I C S S C S S C P L S K I L L A R L F L Y A L 
R a j i L L T L A A A L A L L A S L I L G T L N L T T M F L L M L L W T L W L L I C S S C S S C P L S K I L L A R L F L Y A L 
361 420 
Y 0 0 8 3 5 A L L L L A S A L I A G G S I L Q T N F K S L S S T E F I P N L F C M L L L I V A G I L F I L A I L T E W G S G N R T Y 
B 9 5 - 8 A L L L L A S A L I A G G S I L Q T N F K S L S S T E F I P N L F C M L L L I V A G I L F I L A I L T E W G S G N R T Y 
C B 1 4 0 2 2 A L L L L A S A L I A G G S I L Q T N F K S L S S T E F I P N L F C M L L L I V A G I L F I L A I L T E W G S G N R T Y 
R a j i A L L L L A S A L I A G G S I L Q T N F K S L S S T _ F I P N L F C M L L L I V A G I L F I L A I L T E W G S G N R T Y 
421 480 
Y 0 0 8 3 5 G P V F M C L G G L L T M V A G A W L T V M S N T L L S A W I L T A G F L I F L I G F A L F G V I R C C R Y C C Y Y C 
B 9 5 - 8 G P V F M C L G G L L T M V A G A V W L T V M S N T L L S A W I L T A G F L I F L I G F A L F G V I R C C R Y C C Y Y C 
C B 1 4 0 2 2 G P V F M C L G G L L T M V A G A V W L T V M S N T L L S A W I L T A G F L I F L I G F A L F G V I R C C R Y C C Y Y C 
R a j i G P V F M C L G G L L T M V A G A V W L T V M J S I T L L S A W I L T A G F L I F L I G F A L F G V I R C C R Y C C Y Y C 
481 497 
Y 0 0 8 3 5 L T L E S E E R P P T P Y R N T V 
B 9 5 - 8 L T L E S E E R P P T P Y R N T V 
C B 1 4 0 2 2 L T L E S E E R P P T P Y R N T V 
R a j i L T L E S E E R P P T P Y R N T V 
90 
Results 
Source of cDNA ^ ^ ^ g e Location (base no.) Amino acid change 
1 86 (320 bp) Leucine—Serine 
, B95-8 2 182 (608 bp) Valine—Alanine 
3 228 (746 bp) Leucine—Proline 
1 228 (746 bp) Leucine—Proline CB 14022 
2 258 (836 bp) Isoleucine—Serine 
1 34 (520 bp) Threonine—Proline 
Raji 2 268 (1224 bp) Glutamic acid—Aspartic acid 
3 325 (1393 bp) Serine—Threonine 
Table 14. Amino acid changes observed in the protein sequence of LMP 2 
derived from B95-8, CB 14022 and Raji cell line. 
91 
Results 
3.10 Hydrophobicity analysis 
The method employed in hydrophobicity analysis is HOPP and Woods 
(HOPP.THR). Each amino acid was assigned a score which was an average among 
seven amino acids. The scores were calculated according to the following table 15. 
% 
In the hydrophobicity analysis graph, the hydrophilicity region was indicated in the 
plus area while the hydrophobicity region is indicated in the minus area. The index 
ranges from -3 to +3, -3 being the most hydrophobic while +3 being the most 
hydrophilic. Each asterisk (*) on the plot corresponded to the amino acid symbol 
below. The upper row of amino acid symbols referred to hydrophilic amino acids 
whereas the lower row refers to hydrophobic amino acids. Only a portion of the 
hydrophobicity plot was shown where amino acid substitutions were detected. 
Amino acid Table value Amino acid Table value 
Alanine -0.50 Leucine -1.80 
Arginine 3.00 Lysine 3.00 
Asparagine 0.20 Methionine -1.30 
Aspartic acid 3.00 Phenylalanine -2.50 
Cysteine -1.00 Proline 0.00 
Glutamine 0.20 Serine 0.30 
Glutamic acid 3.00 Threonine -0.40 
Glycine 0.00 Tryptophan -3.40 
Histidine -0.50 Tyrosine -2.30 
Isoleucine -1.80 Valine -1.50 
Table 15. Values used to predict the hydrophobicity index. 
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Results 
3.10.1 Comparison of hydrophobicity of B95-8-derived LMP 2 with 
GeneBank 
An amino acid substitution occurred at position 86 where a leucine (L) was 
changed into serine (S). Bold and shadowed-amino acid symbol indicated substituted 
amino acid residue. Serine was more hydrophilic than leucine but such change had not 
> 
significantly altered the original hydrophobic context of residue 80 to 90. 
GeneBank 
Index 
3 + + + + + + + 
I I I I I I I 
2 + I 丨 I 丨 丨 I 
I ^ I � I I •k 女 女 I •k I 
1 + ^ ^ ^ � I • • I • * I • ^  I 
I + ^ ^ * � I + •k ^ * � * 女 ~k � 
I • ^ I * * I ^ I 女 卡 女 女 I ^ I + + 1 
一 1 + ^ I I 女 女 + 女 I � I 女 
I I I I I I I 
-2 + 丨 I I 丨 I I 
I i I I I I I 
-3 + + + + + + + 
60 70 80 90 100 110 120 
H Y D R O P H I L I C E W G N G D R H P L G T G L Q H D G N D P P Y S P R D D Q H I Y E E A G R 
H Y D R O P H O B I C D P Y S D Y Q Q D Q S L Y L G L P P SS G S M 
B95-8 
Index 
3 + + + + + + + 
I I I I I I I 
2 + 丨 I I 丨 丨 I 
I • I 丨 I 丨 … 丨 * I 
1 + • •k ^ I � •k ^ I -k •k I •k * I 
I * 女 * * � I •k * • •k I 卡 女 * I 
I •k 女 I •^•k I •k •k I ** + * � •k I **I 
-1 + * I I *^ I I 丨 * 
I I I I I I I 
-2 + 丨 丨 I I I I 
I I I I I I I 
-3 + + + + + + + 
60 70 80 90 100 110 120 
H Y D R O P H I L I C E W G N G D R H PLGT | G L Q H D G N D P P Y S P R D D Q H I Y E E A G R 
H Y D R O P H O B I C D P Y S D Y Q Q D Q S L Y G L P P SS G S M 
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The second and third amino acid substitutions occurred at position 182 and 228 
where a valine (V) was changed into alanine (A) and a leucine (L) was changed into proline 
(P) respectively. However, the following two plots were identical which suggested that 
these substitutions had no impact on hydrophobicity of the protein. 
� 
GeneBank 
I n d e x 
3 + + + + + + + 
I I I I I I I 
2 + 丨 丨 I 丨 丨 * I 
I I I I I I I 
1 + I ” I 丨 丨 * * I 
I I ^ ^ ^ ^ I I � + • ^ � 
〇+ ； + 女 + —女 + + + —女 女 女 
I I � 女 I 女 女 女 ^ -k I � I 
_ 1 + * * * * * * I * * � * * � * * * * * I * I 
I 女 女 女 女 女 女 女 I •k 女 女 女 女 | * * * : ; l c * * " 5 ^ * * ^ * I 
- 2 + 丨 I 丨 i I I 
I I I I I I I 
- 3 + + + + + + + 
1 8 0 1 9 0 2 0 0 2 1 0 2 2 0 2 3 0 2 4 0 
H Y D R O P H I L I C T W R I E D L A Y R R R R 
H Y D R O P H O B I C P V T V L T A V V T F F A I C L P P F N S L L F A L L A A A G G L Q G I Y V L V M L V L L I W 
B95-8 
I n d e x 
3 + + + + + + + 
I I I I I I I 
2 + I I I I 丨 * I 
I I I I I I I 
1 + I ” I 丨 丨 * * I 
I I -k S"r -k 女 I I I * • ^ I 
0 + + • + -• + + + -• •• 
I I I + � + 女 * ^ • I I � 
- 1 + * * " ^ * * * I *"^ I * * | * * * • * 1 * I 
I 卡~k^k~k~k女•k I 女 ^ ^ ^ ^ I ^ ^ ^ ^ ^ ^ ^  ^ ^ ^ I 
- 2 + 丨 丨 丨 丨 丨 I 
I I I I I I I 
- 3 + + + + + + + 
1 8 0 1 9 0 2 0 0 2 1 0 2 2 0 2 3 0 2 4 0 
H Y D R O P H I L I C T W R I E D L A Y R R R R 
H Y D R O P H O B I C P | T V L T A V V T F F A I C L P P F N S L L F A L L A A A G G L Q G I Y V L V M | V L L I W 
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3.10.2 Comparison ofhydrophobicity ofCB 14022-derived LMP 2 with 
GeneBank 
An amino acid substitution was observed at position 228 where a leucine (L) was 
changed into proline (P). However, as observed from the graph that this amino acid 
� 
substitution did not alter the hydrophobicity of the CB 14022-derived L M P 2. 
GeneBank 
I n d e x 
3 + + + + + + + 
I I I I I I I 
2 + I I 丨 丨 I * I 
I I I I I I I 
1 + 丨 ” 丨 丨 丨 * * I 
I I 女^ -k女 I � � ~k ^ 女 � 
〇 + + * + — + + + + —• •• 
I I I • I ^ ^  女 ^ • I I I 
_ 1 + * * * * * * � ** � * * | * * * * * I ^ I 
I ^ ^  ^  ^  ^  ^  ^  I 女 ^ ^ ^ ^ I ^  ^  ^  ^ ^ ^ ^ ^ ^ ^ � 
-2 + I I 丨 I 丨 I 
I I I I I I I 
-3 + + + + + + + 
180 190 200 210 220 230 240 
H Y D R O P H I L I C T W R I E D L A Y R R R R 
H Y D R O P H O B I C P V T V L T A V V T F F A I C L P P F N S L L F A L L A A A G G L Q G I Y V L V M L V L L I W 
CB 14022 
I n d e x 
3 + + + + + + + 
I I I I I I I 
2 + I I I 丨 I 女 I 
I I I I I I I 
1 + I *l I 丨 丨 * * I 
� I “^  •k ^ -k I � I 女 女 • I 
0 + + • + - ^ - + + + - • 女 女 
� I I ^ I 女 ^  女• ^ I I I 
_1 +"^ ***** I ** I * * l** *•* I* I 
I -k ^  ^  ^  ^  ~k ^  I • 女 女 女 女 |+S^ *"^  + "^"^"^*"^  � 
-2 + 丨 I I 丨 丨 I 
I I I I I I I 
-3 + + + + + + + 
180 190 200 210 220 230 240 
H Y D R O P H O B I C T W R I E D L A Y R R R R 
H Y D R O P H I L I C P V T V L T A V V T F F A I C L P P F N S L L F A L L A A A G G L Q G I Y V L V ^ ^ L L I W 
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Another amino acid substitution was observed at position 2587 where an 
isoleucine (I) was changed into serine (S). This portion ofLMP 2 pertained to the 
transmembrane domain and was therefore hydrophobic in nature. According to the plot, 




I n d e x 
3 + + + + + + + 
I I I I I I I 
2 + I I I 丨 I I 
I I I I I I I 
1 + 丨 丨 I I 丨 I 
I I I I I I I 
0 + + + + + *** + 
I * I -k * ^ ^ * •k � I |^>t^^^^** � 
_1 + * * * * * � * I***** ********** I ** � * * * * * 
I • • * • ^ * * * � � * * • * • * � � 
- 2 + I 丨 丨 丨 … 丨 I 
I I I I I I I 
- 3 + + + + + + + 
2 4 0 2 5 0 2 6 0 2 7 0 2 8 0 2 9 0 3 0 0 
H Y D R O P H I L I C 
H Y D R O P H O B I C R L T V C G G I M F L A C V L V L I V D A V L Q L S P L L G A V T W S M T L L L L A F V L W L S S P G G L G T L G A A 
CB 14022 
I n d e x 
3 + + + + + + + 
I I I I I I I 
2 + I 丨 I 丨 I I 
I I I I I I I 
1 + I I I 丨 丨 I 
I I I I I I I 
0 + + + + + *** + 
I * I •^^•k^k^^k -k � I ! * * • * * � 
_ 1 + * * * * * I ^ � * * * * * * * * * * * * * * * � ** I * * * * * 
I * ^  ^  ^  * ^  * I I •^•^*••k •k I I 
- 2 + I I 丨 丨 … 丨 I 
I I I I I I I 
- 3 + + + + + + + 
2 4 0 2 5 0 2 6 0 2 7 0 2 8 0 2 9 0 3 0 0 
H Y D R O P H I L I C 
H Y D R O P H O B I C R L T V C G G I M F L A C V L V L _ V D A V L Q L S P L L G A V T V V S M T L L L L A F V L W L S S P G G L G T L G A A 
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3.10.3 Comparison of hydrophobicity of Raji-derived LMP 2B with 
GeneBank 
L M P 2B had only the 12 transmembrane domans and a short non-functional 
carboxyl tail. All three amino acid substitutions identified in the Raji-derived L M P 2B 
� 
amino acid sequence were located in the trensmembrane domain The first occurred at 
position 34 where a theronine (T) was changed into proline (P). However, this 
alteration did not have significantly effect since the hydrophobicity context was very 
much conserved as observed from the plot. 
GeneBank 
Index 
3 + + + + + + + 
I I I I I I I 
2 + I 丨 丨 I I I 
I I I I I I I 
1 + I I I I 丨 * I 
I I 丨 I I I * … I 
〇 + + + + + +-* + 
I • � ^>lt+| • * * * -k ^ •* * •k � *Tt + * + ** * I 
_1 +* * ** � * *** •k *!•^  * * ***I* * I •* 
� * • 女 女 女 女 * * * � � * ^ * � I 
- 2 + 丨 * * 丨 I 丨 丨 I 
I I I I I I I 
- 3 + + + + + + + 
0 1 0 2 0 3 0 4 0 5 0 6 0 
H Y D R O P H I L I C A A A Q R 
H Y D R O P H O B I C M N P V C L P V I V A P Y L F W L A A I A A S C F T A S V S T V V T A T G L A L S L L L L A A V A S S Y K L L 
Raji 
Index 
3 + + + + + + + 
1 I I I I I I 
2 + I 丨 I 丨 丨 I 
I I I I I I I 
1 + I 丨 I 丨 丨 * I 
I I I � � � “^  * ^ ^ I 
0 + + + + + +-• + 
I • I ^ ^ I • • k ^ ^ ~ k ^ - k ^ ^ ^ ^ I ^ ^ ^ ^ ^ ^ ^ - k I 
一 1 + * * * * I • ^ ^ ^ * * l 女 ^ ^ ^ I ^ * � * • 
I • * • • ^ 女 ^  • k ^ ^ • I I • 女 • I I 
- 2 + 丨 * * 丨 丨 I 丨 I 
I I I I I I I 
- 3 + + + + + + + 
〇 1 0 2 0 3 0 4 0 5 0 6 0 
H Y D R O P H I L I C A A A Q R 
H Y D R O P H O B I C M N P V C L P V I V A P Y L F W L A A I A A S C F T A S V S T V V p \ T G L A L S L L L L A A V A S S Y K L L 
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The second amino acid substitution was observed at position 268 where a 
glutamic acid (E) was changed into an aspartic acid (D). Obviously, this change did 
not bring about any alteration in the hydrophobicity of the protein. 
、 GeneBank 
I n d e x 
3 + + + + + + + 
I I I I I I I 
2 + 丨 I I I 丨 I 
I I I I I I I 
1 + 丨 丨 I 丨 丨 I 
I I 丨 • • I I 丨 • I 
Q _| I 女女女女女 女女女女 I I |_ —女女女一女女女女+ 
I •k 女 女 ^ • 女 • I 女 I I •k 女 • � 
—1 + * * * * * * | * I * * *** * � * 
I ^  ^  I I 叫 ^ ^  ^  ^  ^  ^  I ^  ^  ^  ^  ^  -k ^ I I 
- 2 + 丨 丨 I 丨 I I 
I I I I I I I 
- 3 + + + + + + + 
2 4 0 2 5 0 2 6 0 2 7 0 2 8 0 2 9 0 3 0 0 
H Y D R O P H I L I C Q K S E W G S G N 
H Y D R O P H O B I C L A L L L L A S A L I A G G S I L T N F L S S T E F I P N L F C M L L L I V A G I L F I L A I L T R T 
Raji 
I n d e x 
3 + + + + + + + 
I I I I I I I 
2 + 丨 I I 丨 丨 I 
I I I I I I I 
1 + I 丨 I 丨 丨 I 
I 丨 丨 • * I 丨 丨 • I 
Q _| I 女 女 女 女 女 女 女 女 女 I I [ _ — • 女 女 一 女 女 女 女 + 
I 女 ^ ^  ^  ^  •女 I 女 I I • ^  ^  I 
_ 1 _ | _ 女 女 女 女 女 * � • I 女 女 * * * ^ I 女 
I ^  ^  I I ^ I ^  ^  ^  ^  ^  ^  I ^  ^  ^  ^  ^  ^  ^  I I 
- 2 + I I 丨 丨 I I 
I I I I I I I 
- 3 + + + + + + + 
2 4 0 2 5 0 2 6 0 2 7 0 2 8 0 2 9 0 3 0 0 
H Y D R O P H I L I C Q K S E W G S G N 
H Y D R O P H O B I C L A L L L L A S A L I A G G S I L T N F L S S T | F I P N L F C M L L L I V A G I L F I L A I L T RT 
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The last amino acid substitution was observed at position 325 where a serine (S) 
residue was changed into threonine (T). Likewise to the interpretation in amino acid 




I n d e x 
3 + + + + + + + 
I I I I I I I 
2 + I 丨 I 丨 丨 I 
I I I I I I I 
1 + 丨 I 丨 丨 丨 I 
I I I I I I I 
0 + + + + + *** + 
� � •k �• k •k •k •k •k I I •k •k I * * 
_1 + • ******** •^•k I * I *** I * •k � ** I 
|>)t • • � 女 女 女 女 女 * ^ ^ ^ * * * * * * * * * * * � + * * * 1 
- 2 + 丨 I I * I I I 
I I I I I I I 
- 3 + + + + + + + 
3 0 0 3 1 0 3 2 0 3 3 0 3 4 0 3 5 0 3 6 0 
H Y D R O P H I L I C V R 
H Y D R O P H O B I C Y G P V F M C L G G L L T M V A G A V W L T V M S N T L L S A W I L T A G F L I F L I G F A L F G I C C R Y C C Y Y 
Raji 
I n d e x 
3 + + + + + + + 
I I I I I I I 
2 + 丨 I I I 丨 I 
I I I I I I I 
1 + I I I 丨 丨 I 
I I I I I I I 
0 + + + + + *** + 
I I •k � •k •k •k � � •k * � + * _1 + * *••***•* ** I* ** I *** � •k 女 � ** I 
|女 ~h * I •k^k^-ki< •••• + • * * * • * *• ^ * -k � ** + ^1 
- 2 + I 丨 丨 * 丨 丨 I 
I I I I I I I 
- 3 + + + + + + + 
3 0 0 3 1 0 3 2 0 3 3 0 3 4 0 3 5 0 3 6 0 
H Y D R O P H I L I C V R 
H Y D R O P H O B I C Y G P V F M C L G G L L T M V A G A V W L T V M | N T L L S A W I L T A G F L I F L I G F A L F G 工 C C R Y C C Y Y 
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3.11 Protein secondary structure analysis 
3.11.1 Comparison of secondary structure of B95-8-derived LMP 2 
with GeneBank 
Of the three amino acid changes, only the one at position 86 did alter the 
hydrophilic cytoplasmic domain of L M P 2. By comparing the following figures where 
‘ bold and shadowed letter stands for amino acid change and squared area represented 
conformational change, both helix and sheet were converted to tum due to this amino 
acid change. 
GeneBank 
8 0 9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 
H S D Y Q P L G T Q D Q S L Y L G L Q H D G N D G L P P P P Y S P R D D S S Q H I Y E E A G R G S M N P V C L P V I V A P Y L F W L A A I A 
H E L I X h h h h h h h h h h H H H h h h h h h h h h h h h h h h h h 
S H E E T s s s s s s s S S S S s s S S s s s s S S S S S S S S S S S S S S S S 
T U R N T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T 
C O I L C 
B95-8 
8 0 9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 
H S D Y Q P L G T Q D O | S L Y _ G L Q | H D G N D G L P P P P Y S P R D D S S Q H I Y E E A G R G S M N P V C L P V I V A P Y L F W L A A I A 
H E L I X h h h H H H h h h h h h h h h h h h h h h h h 
S H E E T s s s s s s s£ s S S s s s s S S S S S S S S S S S S S S S S 
T U R N T T T T T T T T T T T ] T T T T T T ] T T T T T T T T T T T T T T T T T T T T T T T T T T T T T 
C〇IL C 
3.11.2 Comparison ofsecondary structure of CB-14022 derived LMP 2 
with GeneBank 
Although two amino acid substitutions were detected in the CB 14022-derived 
L M P 2, these changes did not lead to alteration of the protein secondary structure as the 
secondary structure plots of L M P 2 derived from CB 14022 was identical to that of 




3.11.3 Comparison of secondary structure of Raji-derived LMP 2 
with GeneBank 
All three amino acid substitutions identified in Raji-derived L M P 2B did lead 
to conformational change of the protein. Amino acid change at position 34 had caused 
a tum composed of four amino acid residues while the one at 268 had shortened the 
‘ helix and finally the one at position 325 had converted a tum to make a huge helix. 
1. 
GeneBank 
10 20 30 40 50 60 70 
M N P V C L P V I V A P Y L F W L A A I A A S C F T A S V S T V V T A T G L A L S L L L L A A V A S S Y A A A Q R K L L T P V T V L T A V V 
H E L I X h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h H h h H H h h h h h h h h h h h h h h h 
S H E E T S s s s s S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S s S S S S S S S S S S S S S S S 
T U R N T T T T T T T T T 
C〇IL 
Raji 
10 20 30 40 50 60 70 
M N P V C L P V I V A P Y L F W L A A I A A S C F T A S V S T V v j K i S | L A L S L L L L A A V A S S Y A A A Q R K L L T P V T V L T A W 
H E L I X h h h h h h h h h h h h h h h h h h h h h h h h h h h h : i h h h i h h h h h h h h h H h h H H h h h h h h h h h h h h h h h 
S H E E T S s s s s S S S S S S S S S S S S S S S S S S S S S S S S S S S S 3 S S s 3 S S S S S S S S S s S S S S S S S S S S S S S S S 
T U R N T T T T T T T T T T T T T 
C O I L  
2 . 
GeneBank 
2 2 0 2 3 0 2 4 0 2 5 0 2 6 0 2 7 0 2 8 0 
L W T L W L L I C S S C S S C P L S K I L L A R L F L Y A L A L L L L A S A L I A G G S I L Q T N F K S L S S T E F I P N L F C M L L L I 
H E L I X h h h h h h h h H h h h h h h h h h h h h h h h h h h H H H H H h h h h h h h h h h h h h h h h h 
S H E E T S S S S S S S S s s s s S S S S S S S S S S S S S S S S s s S S S S S S s S S S S S S S S S S S S S 
T U R N T T T T T T T T T T T T T T T T T T T 
C〇IL C C 
r 
Raji 
2 2 0 2 3 0 2 4 0 2 5 0 2 6 0 2 7 0 2 8 0 
L W T L V V L L I C S S C S S C P L S K I L L A R L F L Y A L A L L L L A S A L I A G G S I L Q T N F K S ^ S T _ F I P N j L F C M L L L I 
H E L I X h h h h h h h h H h h h h h h h h h h h h h h h h h h H H H H H h ihhhhhhh 
S H E E T S S S S S S S S s s s s S S S S S S S S S S S S S S S S s s S S S S S S s S S S 3SSSSSSS 
T U R N T T T T T T T T T T T T T T T T T T T T T 





2 9 0 3 0 0 3 1 0 3 2 0 3 3 0 3 4 0 3 5 0 
V A G I L F I L A I L T E W G S G N R T Y G P V F M C L G G L L T M V A G A V W L T V M S N T L L S A W I L T A G F L I F L I G F A L F G V 
H E L I X h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h 
S H E E T S S S S S S S S S S S S S s s S S S S s s s s S S S S S S S S S S S S S s s s s S S S S S S S S S S S S S S S S S S S S S S S 
T U R N T T T T T T T T T T T T T T T T T 
C O I L 
* . 
Raji 
2 9 0 3 0 0 3 1 0 3 2 0 3 3 0 3 4 0 3 5 0 
V A G I L F I L A I L T E W G S G N R T Y G P V F M C L G G L L T M V A G A V W L T V M _ L L S A W I L T A G F L I F L I G F A L F G V 
H E L I X h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h 
S H E E T S S S S S S S S S S S S S s s S S S S s s s s S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S 




3.12 Isoelectric point analysis 
The following tables show the number of various charged amino acid 
residues of L M P 2 and their corresponding pKa. The isoelectric points ^ pI) were 
calculated as well. 
� 
• • T 7 T m ^ E B V LMP 2A EBV LMP 2A EBV LMP 2A Ammo acid (pKa) (CeneBank) (B95-8) (CB 14022) 
Aig (12.5) 17 17 17 
Asp (3.9) 14 14 14 
Cys (8.3) 15 15 15 
Glu (4.3) 15 15 15 
His (6.0) 3 3 3 
Lys(10.5) 3 3 3 
Tyr(10.1) 18 18 18 
Table 16. Number of charged amino acids of LMP 2A derived from GeneBank, 
B95-8 and CB 14022 cDNAs. 
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• . . , . ^ � EBV LMP 2B EBV LMP 2B Ammoacid(pKa) (GeneBank) (Raji) 
Arg (12.5) 13 13 
^ Asp (3.9) 2 3 
Cys(8.3) 15 15 
Glu (4.3) 6 5 
His (6.0) 0 0 
Lys(10.5) 3 3 
Tyr(10.1) 10 10 
Table 17. Number of charged amino acids ofLMP 2B derived from the 
GeneBank and Raji cell line. 
Samples Isoelectric points (pI) 
E B V L M P 2A (GeneBank) 4.70 
E B V L M P 2A (B95-8) 4.70 
E B V L M P 2A (CB 14022) 4.70 
E B V L M P 2B (GeneBank) 8.33 
E B V L M P 2B (Raji) 8.33 




Chapter 4 Discussions 
In the present study, the L M P 2 genes ofthree cell lines were amplified by 
PCR, cloned and their D N A sequences were determined from three different E B V 
, transformed cell lines. The cell lines studied included: a) B95-8 cell line; b) Raji cell 
line and c) CB 14022 cell line. These cell lines were chosen to be studied since they 
represent isolates ofEBVs which originated from different EBV-associated diseases. 
B95-8 cell line is primarily a marmoset B lymphocyte line transformed and 
immortalized by EBV.^^^ The EBV-infected cells spontaneously and regularly 
release infectious E B V particles. E B V derived from B95-8 has long been considered 
as the standard strain or wild type ofEBV and used for comparison in many studies. 
Likewise in this study, the D N A sequence of L M P 2, including L M P 2A and L M P 
2B, derived from B95-8 cell line acts as the standard for comparison. 
Another source of L M P 2 comes from the Raji cell line which is B 
lymphocytes derived from an African children suffering from Burkitt,s 
lymphoma.2i4 The B lymphocytes are latently infected by E B V but are defective in 
part of the replicative cycle ofEBV so that they are unable to produce viral particles. 
In addition, Raji cell line contains two major deletions^ ^^  in which one ofthem spans 
the promoter region of latent membrane protein 2A resulting in the inability to 
encode L M P 2A but L M P 2B is not affected. As a result, only L M P 2B can be 
encoded in Raji cell line. The Raji and B95-8 cell lines were well studied and were 
used generally as standards in many studies in molecular biology ofEBV and for the 
elucidation of carcinogenic mechanisms ofEBV. 28，39，4i, 76，80,84，120, i36 
The third source of L M P 2 is the cord blood lymphoblastoid cell line CB 
14022. The CB 14022 cells were cord blood lymphocytes transformed by an E B V 
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isolated from a case of N P C in Hong Kong which contains an E B V genotype 
commonly found to be associated with N P C locally. The E B V in this cell line was 
proven to contain a NPC-specific deletion of 30 bp at the carboxyl terminus with 
specific amino acid substitution Asp at codon 335 with reference to Gly in B95-8 
, LMP1. 191，192 
Results demonstrated that the L M P 2 gene from different sources are highly 
conserved and sequence variability is mainly concentrated within the 12 
transmembrane hydrophobic domains which account for % of the whole L M P 2. 
Although sequence variability exists in L M P 2 gene, it has not been shown to be 
influential to the function of this gene. Function of L M P 2 starts from the 
phosphorylation of the 8 tyrosine residues located at the first 119 amino acid 
cytoplasmic domain/^^' ^ ^^  These tyrosine residues essentially form the basis ofthe 
function of L M P 2. Since none of our identified sequence variability is located on 
these tyrosine residues, function of the phosphorylation domain (the first 119 amino 
acids) ofLMP 2 is appeared to be conserved. 
4.1 Overall strategy for the cloning and sequencing of EBV 
LMP 2 gene 
The strategy used in the study was to extract m R N A s from the three cell 
lines mentioned above and to convert these m R N A s into cDNAs using the enzyme 
reverse transcriptase. To select the required L M P 2A and L M P 2B cDNAs among 
the other cDNAs, two sets of E B V L M P 2A and 2B-specific primers were used in 
the polymerase chain reaction. Two steps were carried out in order to confirm 
whether the PCR has yielded desired results. Firstly, extra sets of inner primers were 
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designed to amplify the first and second half portion of the L M P 2A and L M P 2B 
cDNAs. Secondly, restriction endonucleases which recognize specific D N A 
sequences, cut the L M P 2 D N A into fragments which could be discerned according 
to their sizes as revealed by electrophoresis analysis. Having confirmed the PCR 
X 
product, the D N A bands corresponding to the sizes of L M P 2 gene were isolated and 
purified so as to eliminate impurities and other non-specific products generated in 
PCR. The purified PCR products were ligated to the pGEM-T Easy Vector and 
transfected into competent cells E. coli strain JM 109. Screening of the 
transformants was done by picking white colonies from the LB plates. Before 
proceeding to D N A sequencing, confirming whether the insert is the desired one or 
not is absolutely necessary. Therefore, the plasmid was extracted and subject to 
enzyme digestion which isolated the insert from the vector and the identity of the 
cloned genes was confirmed. 
Subsequent step was to sequence the insert within the plasmid. For obtaining 
better and more accurate results, additional primers were designed so that both sense 
and anti-sense strands of insert D N A were sequenced. 
4.2 Implications of the results obtained in sequencing 
Since E B V L M P 2 is consistently expressed in NPC cells and involved in 
transformation, the L M P 2 gene sequences obtained from various sources in this 
study may therefore provide important information. By comparing the L M P 2 gene 
sequence derived from NPC patients with that of the standard strain, it is expected 
that certain degree of difference may exist. Ifmutations really occur, the question of 
whether these changes pervade to the protein level or just simply silent mutations 
was examined. Furthermore if these mutations truly alter the amino acid 
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composition of L M P 2 gene product, these changes may have significant 
implications on the overall conformation and the functions of L M P 2 which may in 
turn altered cellular functions or immune surveillance in N P C patients. Aims of this 
study were to examine such occurrence using E B V strains isolated from different 
sources. 
4.3 Results interpretation 
4.3.1 Cell culture 
The B95-8, Raji and CB 14022 cell lines had shown exponential growth 
when culturing in the RPMI 1640 medium supplemented with 15% fetal calf serum. 
According to table 7, the growth rates of the B95-8 and Raji cell lines were 
comparable whereas CB 14022 cell line grew a little slower under the same 
conditions. This indicates that the conditions used for culturing B95-8 and Raji cell 
lines may not be equally favorable to CB 14022 or that specific conditions of growth 
may be required. 
4.3.2. Extraction oftotal RNA 
Electrophoresis analysis of the extracted total R N A of the three 
samples had shown consistent results. Lane 1 of figures 7,8 and 9 showed the 
undiluted total R N A which, as expected, formed a smear along the lane. The smear 
represented the ribosomal R N A (rRNA) which is the most abundant R N A in cells. 
Other than rRNA, messenger R N A (mRNA), transfer R N A (tRNA) are components 
of total R N A but their quantities are much less than rRNA. Lane 2 represented total 
R N A diluted 10 times where the smear became lessened. Two D N A bands were 
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observed in Lane 3 where the total RNAs were diltued 100 times. After a 100-times 
dilution, tRNA and m R N A were too dilute to be seen and what became visible was 
primarily the more abundant rRNA. The upper band referred to the bigger 23S 
rRNA, having an approximate size of 1.5 kbp. The lower band referred to the 
’ smaller 16S rRNA sized approximately 0.8 kbp. The smallest 5S rRNA was too 
small to be seen on the gel. 
4.3.3 PCR amplification 
The first strand cDNA synthesis and PCR of the L M P 2 gene derived from 
the three cell lines had yielded desirable results since each D N A band corresponded 
well with the expected size. The amplified L M P 2A cDNA matched with the 2027 
bp marker, the actual size being 2008 bp, and the amplified L M P 2B cDNA located 
between the 1353 bp and 2027 bp markers, the actual size being 1587 bp. Non-
specific bands were not observed so far which indicated that the running conditions 
of the PCR had been optimized. The primers used were specific to the E B V L M P 2 
gene and the reagents were clean as shown in each of the cDNA and PCR reagent 
control. As expected, all the negative controls did not show any band. This meant 
that contamination did not occur during the whole course of cell culture. 
4.3.4 Confirmation of the PCR amplified cDNA using nested PCR 
The aim of this nested PCR is to amplify the first and second portions of the 
L M P 2A and L M P 2B cDNAs using two sets of E B V L M P 2A and 2B-specific 
primers. This was a very first step to confirm whether our PCR amplified cDNAs 
were our desired ones. For amplification of the first and second portions ofLMP 2A, 
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positive results would yield a band at 1062 bp and 945 bp respectively. For 
amplification of the first and second portions of L M P 2B, positive results would 
yield a band at 642 bp and 945 bp respectively. As observed from the figures, our 
results coincided with what had been predicted. 
� 4.3.5 Confirmation of the PCR amplified cDNA using restriction 
enzyme digestion 
Another approach had been used to further ensure the PCR amplified cDNAs 
were the correct ones. Since the E B V L M P 2 contained specific restriction sites 
where restriction enzymes can recognize and digest. Two of these enzymes, Hincll 
and Ncol, digested specifically at restriction sites GTY>^RAC and C^^CATGG 
respectively. Hincll hydrolysed the only restriction site and divided the L M P 2A 
into two fragments, one at 840 bp and the other at 1168 bp in size. For L M P 2B, 
Hincll divided it into 421 bp and 1168 bp. Likewise, Ncol cut the only restriction 
site and divided the L M P 2A into two fragments, one at 1358 bp and the other at 650 
bp. For L M P 2B, Ncol divided it into 939 bp and 650 bp. 
The sizes of various enzyme-digested products all matched with that 
expected from above. As observed from figures 18-21, each lane showed two 
distinct bands with expected sizes. 
Coupling the results from nested PCR and restriction enzyme digestion, the 
identities of the PCR amplified cDNAs were very likely confirmed to be L M P 2A 
and L M P 2B. 
4.3.6 Ligation ofEBV LMP 2 cDNA to pGEM-T Easy Vector 
It is well known that many of the thermostable enzymes like Taq polymerase 
used in PCR produce protruding 3 ‘ -deoxyadenosine residue in the PCR product. 
Conventional methods usually remove the single 3’ A overhang for blunt-end 
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ligation. However, the method employed in this study did make use of this A 
overhang. The pGEM-T Easy Vector was specially prepared by cutting the vector 
with EcoR V and adding a 3' terminal thymidine to both ends. These single 3'-T 
overhangs at the insertion site greatly improved the efficiency of ligation of a PCR 
‘ product into the plasmids by preventing recircularization ofthe vector and providing 
a compatible overhang for PCR products carrying the A overhang. 
The possible outcomes of the ligation reaction include the following: 
1. Recircularization of the vector which meant that the ligation reaction failed. 
2. Two or more L M P 2 inserts ligated together and inserted into the multiple cloning 
site (MCS) ofthe vector. 
3. The final possibility is that only one L M P 2 insert was ligated to the vector. 
Among the three outcomes, number 3 was only desirable and could be 
achieved by optimizing the vector : insert ratio to 1:1. This could be done by 
measuring the concentrations ofplasmid and adjusting the amount that was going to 
be added. 
The high copy number pGEM-T Easy Vector, having a length of 3 kbp, 
possesses an ampicillin resistant gene and a lacZ' gene located on the multiple 
cloning site (MCS) that encodes for the a-peptide portion of the enzyme p_ 
galactosidase. The missing part is encoded by a gene locating on the E.coli 
chromosme. So that the bacteria should undergo a-complementation in order to 
produce a fully functional P-galactosidase which is responsible for breaking down 
lactose into galactose and glucose. Insertion of the L M P 2 cDNA into the multiple 
cloning site of the pGEM-T Easy Vector would disrupt the lacZ' gene and thus p-
galactosidase was not encoded. These facts are extremely useful in screening and 
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distinguishing the desired clone during transformation. A full picture of pGEM-T 
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4.3.7 Transformation and screening 
The ligation of fragments with a single-base overhang could be inefficient, 
so it was essential to use cells that are lxlO^ cfu/^g D N A in order to obtain a 
reasonable number of colonies and E.coli strain JM 109 was one of them. In fact, 
X 
most species of bacteria, including E.coli, take up only a limited amount of D N A 
under normal circumstances. One way to enhance their ability for the cells to take up 
D N A was by heat-shock. By placing the cells on ice for 20 minutes and then 
transferring them immediately into a water bath at 42°C, their cell membranes would 
become temporarily permeable for D N A uptake. 
Of course, transformation using heat-shock was not 100% efficient. Some 
of the bacterial cells were still unable to take up plasmids. Therefore, coupling the 
three possible outcomes in the process of ligation mentioned previously, we were 
confronted with a total of four possibilities: 
A. The bacterial cell did not up any plasmid. 
B. The cell took up a plasmid without the L M P 2 insert. 
C. The cell took up a plasmid with multiple inserts. 
D. The cell took up a plasmid with only one L M P 2 insert. 
The four types ofbacterial cells manifested their growth patterns differently 
when they were plated out on LB plates supplemented with X-gal (a lactose 
analogue), JPTG (isopropyl-thiogalactoside, inducer of enzyme p_galactosidase.) 
and ampicillin.i85 X-gal could be broken down by P-galactosidase to yield a blue 
185 
product otherwise if p-galactosidase was absent, the colonies appeared white. 
E.coli strain JM 109 were ampicillin resistant and unable to produce an intact P_ 
galactosidase. They had to acquire the a-peptide portion from the lacZ，gene on the 
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pGEM-T Easy Vector in order to produce P-galactosidase. Therefore, Outcome A 
which was simply E.coli JM 109 did not show growth on the plate because it failed 
to acquire the ampicillin gene from the vector. Outcome B showed growth since the 
bacteria had acquired the pGEM-T Easy Vector and were therefore ampicillin 
‘ resistant. The lacZ' genes were still intact so that P-galactosidase could be produced 
and the colonies should appear blue colonies. For Outcome C and D, they both 
showed growth but appeared as white because the lacZ' gene were disrupted by the 
L M P 2 inserts. At this point, we were not able to discem Outcome C and D until 
next section. 
According to table 10 on p.77, as expected both blue and white colonies 
were observed in all samples and the frequencies of blue colonies obviously 
outnumber that of white colonies. In addition, more white colonies were observed 
for L M P 2B as insert than that ofLMP 2A as insert. This might due to the fact that 
L M P 2B cDNA was 500 bp shorter than L M P 2A cDNA and shorter inserts were 
easier for ligation and transformation. 
4.3.8 Extraction of plasmid DNA and digestion with restriction 
enzyme 
Determination of whether the ligation and transformation was successful 
could be accomplished by plasmid digestion with EcoRl which cut the two 
restriction sites flanking the L M P 2 insert. Before proceeding, extraction and 
purification of plasmids were absolutely necessary so as to avoid non-specific 
digestion with EcoRl. Secondly, extraction of plasmid provided the source for D N A 
sequencing. 
Extraction of the plasmid with the L M P 2 insert required digestion and 
removal of the cell membranes, chromosomal D N A and cellular proteins and nucleic 
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acids. After digestion with EcoRl, a band of L M P 2 and a band referring to the 
pGEM-T Easy Vector should appear on gel electrophoresis. L M P 2A and L M P 2B 
corresponded to 2.0 kbp and 1.5 kbp respectively while the pGEM-T Easy Vector 
had a size of 3.0 kbp. As expected, all the EcoRI-digested plasmids had shown two 
， distinct bands with predicted sizes. For the undigested plasmids, 2 to 3 bands were 
observed. One of them sized at 4.5-5.0 kbp is of course the pGEM-T Easy Vector 
with the L M P 2 A or 2B insert. The band above it, locating between markers 0.9 kbp 
and 23.0 kbp, might refer to chromosomal D N A . This was the only explanation 
since only chromosomal D N A would have such a huge size. Presence of 
chromosomal D N A might be to imperfect purification of plasmid but after EcoRl 
digestion, this band had disappeared. Another band was observed at about 3 kbp. 
This was actually the pGEM-T Easy Vector plus L M P 2 insert but what made it 
different from the normal band was its altered conformation. The simple circular 
plasmid, termed relaxed form, could form a supercoiled structure. Supercoiling 
markedly altered the overall form of D N A . A supercolied D N A molecule was more 
compact than a relaxed D N A molecule of the same length. Hence, supercoiled D N A 
moved faster than relaxed D N A when they were electrophoresed. 
4.4 DNA sequencing and sequence homology 
A total of seven pairs of forward and reverse primers were required to 
sequence both the sense and anti-sense L M P 2 gene sequence (2008 bp) since for 
automated sequencing, each primer could cover up 300 to 400 bases. In addition, in 
order to avoid the possibility of misidentifying mutations due to the problem with 
fidelity of Taq polymerase and reverse transcriptase, the L M P 2 genes were cloned 
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and three clones had been sequenced and results showed the same mutations in 
different clones. 
Using sequences derived from GeneBank as the standard (Accession 
no.:Y00835), 5, 6 and 9 base changes were detected in B95-8-, CB 14022- and Raji-
' derived L M P 2 D N A sequences respectively. These base changes were both 
detected in the sense and anti-sense strands so that these changes could not be due to 
errors or misreading. Anyway, the overall percent matches were 99.7%, 99.8 % and 
99.4% respectively which shared extensive homology with the standard. At this 
point, however, we could not conclude whether these base changes were going to 
affect much at the protein level since some of them might be silent mutations. 
4.5 Amino acid sequence homology 
For B95-8 and CB 14022-derived L M P 2A, translation started at base 64 in 
exon 1 and stopped at base 1554 in the end of exon 8. For Raji-derived L M P 2B, 
translation started at base 421 in exon 2 and terminated at base 1554 at the end of 
exon 8. Therefore, the entire exon 9 ofLMP 2 was non-encoding. 
After D N A sequence being translated into amino acids, the B95-8-derived 
L M P 2A exhibited three amino acid changes listed in table 15. Therefore, of the five 
base changes discovered previously, two of them were silent mutations. The overall 
percent match was calculated to be 99.4%. 
The CB 14022-derived L M P 2A had shown two amino acid changes listed in 
table 16. As a result of the six base changes, four ofthem were silent mutations. The 
overall percent match is 99.4%. 
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For the Raji-derived L M P 2B, three amino acid changes had been detected as 
listed in table 17. Of the nine base changes, six of them were silent mutations. The 





4.6 Hydrophobicity analysis 
The hydrophobicity of a protein molecule is significant to its secondary 
structure and conformation. According to the fact that hydrophilic regions of a 
molecule are "water-loving", hydrophilic regions are usually strongly charged and 
X 
tend to expose themselves outwardly in a polypeptide so as to mix with the polar 
water molecules. In contrast, hydrophobic regions are non-polar and tend to fold 
inwardly to give maximum entropy. For example in a membrane protein, 
hydrophobic regions are likely to bury into the hydrophobic transmembrane domain. 
As a result, hydrophilic regions are more likely than hydrophobic regions to induce 
antibody formation and as epitopes for cytotoxic T lymphocyte (CTL) response. So 
that hydrophilic regions of a protein molecule are considered to be immunodominant 
regions and the aim of this analysis is to observe whether these regions are mutated 
or new immunodominant regions arise. 
The whole hydrophobicity plots (not shown) of E B V L M P 2A derived from 
GeneBank, B95-8 and CB 14022 had suggested a membrane protein. The first 119 
amino acids, as expected, were located in the hydrophilic region and were the 
functional domain of E B V L M P 2A whereas the rest of the 378 amino acids were 
more or less located in the hydrophobic region. These 378 amino acids transversed 
the transmembrane domain acting as an anchorage for the membrane protein. Of the 
378 amino acids, some 4 to 8 amino acid residues intermittently located in the 
hydrophilic region. These were the tums of the transmembrane domains protruding 
up to the extracellular side so that they were hydrophilic and they were expected to 
be immunogenic. Returning to the plots, the more positive the index, the more 
hydrophilic the residue was and thus the more immunogenic it can be. 
119 
Discussion 
Three amino acid changes were detected in the B95-8-derived E B V L M P 
2A. A leucine had been substituted to serine at position 86 where it lied in the first 
119 amino acid hydrophilic domain. Serine was more hydrophilic than leucine since 
it possessed an extra hydroxyl group. However, the overall hydrophobic context has 
� 
not been altered due to this amino acid substitution. The second and third amino acid 
changes occurred at positions 182 and 228 respectively where they were both 
located in the transmembrane domain. However, these changes had not altered the 
overall hydrophobic backgrounds. 
For the CB 14022-derived E B V L M P 2A, two amino acid changes occurred 
in the hydrophobic transmembrane domain at positions 228 and 258. These 
substitutions, as observed in the plot, had not been shown to bring about significant 
changes in their respective overall hydrophobic contexts. 
L M P 2B, lacking the first 119 hydrophilic amino acids, only had the 12 
hydrophobic transmembrane domains and the short carboxyl terminus. In the Raji-
derived E B V L M P 2B, three amino acid changes were found at positions 34, 268, 
and 325 respectively. The original contexts of the three substitutions were all 
hydrophobic. However, the three substitutions had not altered the plot significantly 
and therefore, the resulting contexts still remain hydrophobic. 
4.7 Protein secondary structure analysis 
The secondary structure of a protein is revealed by its way of folding. 
Folding includes a-helix, P-sheet, tum and coil. Secondary structure plays an 
important role in protein function and immunogenicity. For example if the 
conformation of an enzyme active site has been altered, the substrate may no longer 
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be able to bind and the whole reaction is therefore blocked. On the other hand, 
altered conformation may change the orientation of the epitopes so that the host may 
elicit different immune responses against this protein. In previous studies^ ^^ ' ^ ^^ , 7 
conserved cytotoxic T lymphocyte epitopes within the L M P 2 were identified in 
� 
peripheral blood E B V isolates of normal individuals from different world 
populations, nasopharyngeal carcinoma and Hodgkin's disease biopsy samples. 
These 7 epitopes were located in residues 200-208, 236-244，329-337，340-349， 
419-427, 426-434 and 453-461 where these epitope sequences were all located in 
the 12 transmembrane domains. 
Of the three amino acid substitutions observed in B95-8-derived E B V L M P 
2A, only the one at position 86 altered the protein conformation, converting itself 
and adjacent amino acid residues into tums as shown in the highlighted area of 
section 3.11.1. However, this change was not located within any of the seven 
epitopes mentioned above and since it occurred in the cytoplasmic domain, 
therefore, this substitution may not be of importance immunologically. 
Results have shown the secondary structure of CB 14022-derived E B V L M P 
2A was exactly identical to that derived from GeneBank. Although there were two 
amino acid substitutions, they had not affected the overall secondary structure. 
Three amino acid substitutions were found in Raji-derived L M P 2B at 
positions 34, 268 and 325. None of them lied in the 7-epitope sequences and 
therefore, these substitutions did not affect immunogenicity of L M P 2B. 
Nevertheless, the one at position 34 had introduced a tum around it and the one at 
position 325 had converted to a helix from a tum. 
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4.8 Isoelectric point analysis 
The isoelectric point ( p l ) of a protein is the pH at which its net charge is 
zero. The pI of a protein is calculated according to the pKas of each amino acid. The 
charge of a protein affects its secondary structure and functions a great deal. E B V 
� 
L M P 2A (GeneBank) is an acidic membrane protein with pI estimated to be 4.70. In 
contrast, L M P 2B is basic protein with a pI of 8.33 because a number of acidic 
amino acids present in L M P 2A are missing. 
Although amino acid substitutions were present in the B95-8- and CB 
14022-derived L M P 2A, these had not affected the number of charged amino acids 
listed in table 16. As aresult, their pIs were all equal to 4.70. 
For the Raji-derived L M P 2B, two of the three amino acid substitutions had 
actually affected the number of charged amino acids by increasing one aspartic acid 
and reducing one glutamic acid. However, levelling off the effect, the pI remained 
unchanged at 8.33. 
4.9 Summary of results 
B95-8-derived E B V L M P 2A, E B V L M P 2A derived from a Chinese male 
nasopharyngeal carcinoma patient (CB 14022) and Raji-derived L M P 2B were 
successfully cloned and sequenced. The D N A sequences were then translated into 
amino acids and both sequences were compared with the standard E B V L M P 2 from 
GeneBank. For subsequent investigation, the amino acid sequences were further 




All three samples, B95-8, CB 14022 and Raji had shown 5, 6 and 9 base pair 
changes respectively within the L M P 2 when compared to the standard. Almost all 
the base pair changes were found in the 12 transmembrane domain except one, 
pertaining to B95-8, where it was located in the intracellular cytoplasmic domain. Of 
� . 
these single base pair substitutions, only 3/5, 2/6 and 3/9 (according to the above 
order) were actually causing non-conservative amino acid changes. Likewise, all the 
discrepancies were almost found in the 12 transmembrane domains except the one 
pertaining to B95-8 where it was located within the first 119 amino acid cytoplasmic 
domain. 
Hydrophobicity analyses of the three samples of L M P 2 had not obviously 
changed their corresponding contexts ensued from these amino acid substitutions. 
All of their contexts remained hydrophobic as they used to be in the standard strain. 
Protein secondary structure analyses of the three sources of L M P 2 had not 
shown major conformational alterations. Minor changes were observed only in the 
regions spanning the cell membrane and were therefore not of immunological 
significance. 
Results of isoelectric point analyses were most consistent with that of the 
standard. pIs ofthe B95-8- and CB 14022-derived L M P 2A were recorded at 4.70 
whereas pI of Raji-derived L M P 2B was recorded at 8.33. The two readings 




This study aims at characterizing and comparing the E B V latent membrane 
protein 2 gene from various sources. By comparing the D N A sequences obtained 
with that of the GeneBank, surprisingly, almost equal number of base pair 
X . 
substitutions were observed in that of B95-8, the standard strain, and the N P C 
patient-derived (CB 14022) L M P 2 since we expected that the CB 14022 will 
exhibit more base pair changes. Moreover, of these substitutions in B95-8, only 
three of them resulted in non-conservative amino acid changes, outnumbering the 
CB 14022 by one. According to two of the studies^ ^^ ' ^^ ^ carried out by Pierre 
Busson et al who identified several hot spots ofbase pair and amino acid changes in 
L M P 2 expressed in NPC patients, however, none of our identified base pair 
changes lied within those hot spots. Perhaps in other words, we might have 
identified some new spots ofmutation but this had yet to be confirmed in the future. 
In addition, the L M P 2A exon 1 which was the functional domain of the 
membrane protein and was responsible for binding cellular protein kinases in signal 
transduction, did not show any amino acid change in our sample, CB 14022. In 
• 1 0 0 
contrast, four major amino acid changes were identified previously in the first 
exon ofLMP 2A cDNA derived from most of the NPC patients. Therefore, coupling 
both previous and our results, the E B V L M P 2 gene might exhibit sequence 
polymorphism especially in the first exon of L M P 2A. Nevertheless, additional 
samples from N P C patients should be further analysed for confirmation. 
In hydrophobicity, secondary structure and isoelectric point analyses of the 
CB 14022-derived L M P 2 had yielded results very much consistent with the 
standard. Sequences of all epitopes coincided with that of the previously reported 
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epitopesi86' 187，implying that the immunogenicity was conserved. In fact, 
constructing a three-dimensional model in a computer display was a more accurate 
way to view the conformation of L M P 2. This model could then serve as an 
excellent basis for identifying amino acid residues involved in antigenic epitopes, 
•%. 
and could be used for further immunological studies such as diagnostic marker 
development. The first step of making such model was to crystallise the protein 
because crystals could diffract x-rays to high resolution. However, membrane 
proteins were very difficult to crystallise because they had both hydrophobic and 
hydrophilic regions which made them insoluble in aqueous buffer solutions and 
denature in organic solvents. 
Functions of the CB 14022-derived L M P 2 in affecting cellular signal 
transduction and preserving E B V in a latent state should not be altered since its 
functional domain, exon 1，had not exhibited any genotypical change. Indeed, 
conserved functions of L M P 2 was apprehensible since this membrane protein is 
consistently expressed in N P C cells and is indispensable in blocking reactivation of 
E B V in B lymphocytes. On top of that, L M P 2 was expected to play a role in the 
oncogensis of nasopharyngeal carcinoma^，i9i although the mechanism was largely 
unknown yet. 
The subsequent step of this study was to express this protein by inserting the 
L M P 2 c D N A into an expression vector such as the baculovirus. Future endeavours 
would be emphasised on the immunological profiles of this E B V L M P 2 in N P C 
patients in Hong Kong. Results would be helpful in the development of an early 
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